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Abstract 
Hypercholesterolemia accelerates the progression of atherosclerosis, the early 
stage of many cardiovascular diseases. Octadecaenoic acids and polyphenols are 
commonly consumed as functional foods to control blood cholesterol. However, 
information on the efficacy and underlying mechanism of their hypocholesterolemic 
activity is currently limited. 
The objectives of the present study were (i) to investigate the differential effects 
of four structurally similar octadecaenoic acids, namely linoleic acid (LA), conjugated 
linoleic acid (CLA), linolenic acid (LN) and conjugated linolenic acid (CLN) on blood 
cholesterol in hamster, (ii) to study the effects LA, CLA and LN on 
cholesterol-regulating genes in HepG2, and (iii) to investigate the effect of apple 
polyphenols (AP) on blood cholesterol in hamsters. 
The results showed that LA, CLA, LN but not CLN significantly lowered blood 
total cholesterol in hamsters. These fatty acids had no effect on blood 
high-density-lipoprotein (HDL) cholesterol but LA, CLA and LN but not CLN reduced 
non-HDL cholesterol, affecting the blood lipid profile favorably. CLA and LN were 
found to reduce liver cholesterol more potently than LA and CLN, but Western blotting 
demonstrated that these four fatty acids had no effect on the sterol regulatory 
element-binding protein-2 (SREBP-2), 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMGR), low-density-lipoprotein receptor (LDLR), liver-X-receptor (LXR) 
and cholesterol-7a-hydroxylase (CYP7A1), and real-time PCR showed no effect on the 
niRNA of cholesterol ester transfer protein (CETP), LDLR, LXR, and CYP7A1. 
ii 
However, it was found that fecal neutral output was increased by CLA and LN，but not 
LA and CLN. Correspondingly, measurement of the intestinal acyl cholesterol: acyl 
transferease (ACAT) activity showed decreased ACAT activity in hamsters fed CLA and 
LN but not LA and CLN, suggesting that the stronger hypocholesterolemic activity of 
CLA and LN over LA and CLN was mediated by their effect on intestinal cholesterol 
absorption via inhibition on intestinal ACAT activity. 
CLA but not LA and LN significantly increased the mRNA level of SREBP-2, 
HMGR, LDLR, LXR, and CYP7A1 in HepG2 cells. Interestingly, CLA only 
significantly increased the protein level of LXR but not that of SREBP-2, LDLR and 
CYP7A1 under the current experimental condition. This suggested CLA had a 
distinctive effect on SREBP-2, HMGR, LDLR, and CYP7A1 gene expression in vitro, 
compared with LA and LN. 
Supplementation of 0.3 and 0.6% of AP in diet had no significant effect on the 
blood total cholesterol in hamsters, but it decreased the non-HDL-cholesterol to 
HDL-cholesterol ratio and blood triglyceride. AP supplementation at both 
concentrations did not significantly affect liver cholesterol level, and had no effect on 
the protein level of SREBP-2, HMGR, LDLR and CYP7A1 in the liver, and CETP in 
plasma. However, plasma CETP activity in both AP fed groups was significantly lower 
than the control, leading to a lower ratio of non-HDL-cholesterol to HDL-cholesterol in 
AP fed hamsters. In vitro experiments also confirmed inhibitory effect of AP on CETP 
activity, suggesting that the decrease in non-HDL-cholesterol to HDL-cholesterol ratio 
by AP was mediated through inhibition on plasma CETP activity at a post-translational 
level. 
iii 
In conclusion, the present study confirmed that LA, CLA and LN were effective 
in reducing blood total cholesterol, while AP was effective in lowering 
non-HDL-cholesterol to HDL-cholesterol ratio. CLA and LN significantly reduced 
intestinal AC AT activity and hence cholesterol absorption in vivo in hamsters. In HepG2 
cells, CLA had a distinctive stimulatory effect on SREBP-2, LDLR, HMGR, LXR and 
CYP7A1 mRNA compared with LA and LN. AP inhibited plasma CETP activity and 























此外，細胞培養實驗表明’ CLA顯著提高了 H e p G 2細胞內 S R E B P - 2 , HMGR, 
LDLR, L X R和C Y P 7 A 1的核糖核酸，但L A和L N則無此效用� C L A亦提高了 LXR 









總之，本硏究証實了 L A � C L A和L N對降血膽固醇之功效，亦証明了蘋果 
多酣可降低非高密度脂蛋白膽固醇/血清高密度脂蛋白膽固醇比例。在活體內，CLA 
和LN通過抑制ACAT，減少腸臟膽固醇吸收；而在試管實驗，CLA則表現了對 
SREBP-2, LDLR, HMGR, LXR和CYP7A1核糖核酸的獨特促進反應。蘋果多酣則通 
過抑制CETP改善活體內膽固醇在血液脂蛋白之分佈。 
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1.1. Introduction to Cholesterol and Its Related Diseases 
1.1.1 Chemistry of cholesterol 
Cholesterol was first discovered in bile stone by Chevreul in 1816. Recognized 
as both a lipid and a sterol, pure cholesterol is an alcohol-soluble white crystal. Its 
chemical structure was confirmed by Bemal (1932) using X-ray crystallography. 
The chemical structure of cholesterol is shown on Figure 1.1. The core 
structure of cholesterol is its steroid nucleus which is built from four fused 
hydrocarbon rings. The steroid nucleus contains three 6-carbon and one 5-carbon 
rings and is relatively planar and rigid, as rotation is not allowed around the C-C 
bonds. A cholesterol molecule also contains two functional groups, a polar hydroxyl 
group and a non-polar alkyl group, making it amphipathic (Nelson & Cox, 2002). 
Cholesterol is transported and stored in the form of cholesterol esters. Being 
insoluble in water, it is circulated in the blood in lipoproteins carriers, including 
high-density lipoprotein (HDL), intermediate-density lipoprotein (IDL), low-density 
lipoprotein (LDL), very low-density lipoprotein (VLDL) and chylomicron. 
1.1.2 Physiological importance of cholesterol 
The major roles of cholesterol are as an essential component in cell membranes 
and as a precursor of a number of hormones. Cholesterol accounts for over 10% of the 
total lipids in plasma membrane and in the Golgi membrane (Meisenberg & Simmons， 
2006). Cholesterol weakens the Van der Waals interaction between the phospholipids 
tails in the bilayer and maintains fluidity of the membrane (Cooper, 1978; Petrache et 





Chemical structure of cholesterol 
The hydroxy I group at A ring of cholesterol is hydrophilic and the rest of 
the molecule is hydrophobic. A fatty acid condenses with this hydroxy I group 
when cholesterol is transported or stored in esterified form. The four rings of 
the nucleus are named A, B, C and D as shown. 
2 
molecules by its characteristic simultaneous hydrophobicity and hydrophilicity 
(Subczynski & Wisniewska, 2000). 
Cholesterol also acts as the precursor of a number of steroid hormones, e.g. 
adrenocortical hormones and sex hormones. Typically, the side chain from the D ring 
of cholesterol is removed and the molecule is oxidized by endocrine tissues and 
carried in the blood to target cells. These steroid hormones couple with nuclear 
receptors and regulate gene expression. Some other hormones, such as progesterone, 
Cortisol, aldosterone, testosterone and cholecalciferol (vitamin D3) are also 
synthesized from cholesterol. These enzymes affect sexual development, sexual 
behavior, calcium deposition and mobilization and a variety of other homeostatic 
functions and hence are important to normal body functioning (Nelson & Cox, 2002). 
1.1.3 Pathological effects of cholesterol 
The most severe clinical manifestation of excessive cholesterol accumulation is 
atherosclerosis, which is referred to as the hardening or furring of the artery wall. 
Atherosclerosis of the coronary and brain artery may progress to coronary heart 
disease and stroke, respectively (Ross, 1993). In 2006, these two cardiovascular 
events together contributed to 24.1% of total mortality in Hong Kong (Department of 
Health, Hong Kong, 2007). 
1.1.3.1 Mechanism of atherosclerosis 
The development of atherosclerosis is slow and progressive. Progression of the 
disease from onset to symptomatic stage may last for years (Figure 1.2). Traditionally, 
atherosclerosis had been simply considered as the gradual accumulation of fatty 
substances on the wall of blood vessels, and is equivalent to the building up rust in 
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Figure 1.2 
Schematic diagram on the progression of coronary atherosclerosis 
Fatty streak build-up results in the formation of plaques. When plaque rupture 
occurs, the exposed tissues clot rapidly, leading to vessel obstruction. 
Adapted from Libby & Theroux (2005). 
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water pipe (Libby, 2006). It is now understood that several immune responses are 
involved in disease progression and plaque forms within the blood vessel tissues 
rather than in the lumen (Libby, 2002). Acute cardiovascular events usually occur 
after the rupture of previously formed plaques, resulting in clot formation of thrombus 
(Libby, 2002). 
Atherosclerosis is initiated by the formation of lesion. When endothelial cells of 
the artery are affected by risk factors, e. g. certain bacterial products, dyslipidemia, 
vasoconstrictor hormones or proinflammatory cytokines, cell injury is induced, 
releasing adhesion molecules that attract the blood leukocytes to stick on (Ramos et al, 
article in press). The leukocytes then transmigrate to the subendothelium, as attracted 
by the chemoattractant cytokines stimulated by the cardiovascular risk factors (Libby 
& Theroux, 2005). Smooth muscle cells then continue to grow around the plaque as 
fibrous caps. Dyslipidemia, on the other hand, promotes the invasion of fatty 
substance-rich LDL and VLDL into the artery, where such lipoproteins are ingested 
by the leukocytes and become oxidized. This leads to the build up of fatty streak 
along the artery, followed by calcification and reduced elastic recoil of the vessel 
(Aikawa & Libby，2004; Tang et al, 2006). 
Plaque deposition does not necessarily lead to stenoses (narrowing of blood 
vessels) and most plaques actually grow outward rather than inward (Amett et al, 
1979)，although some may progress in sudden spurts rather than continuously during 
ruptures (Bruschke et al, 1989; Yokoya et al, 1999). In plaque ruptures, the fatty 
tissues are released and exposed, promoting clot, leading to thrombus (blood clot), 
which may result in lumen closure. Closure in coronary artery may rapidly and 
suddenly reduce blood flow (and hence oxygen supply) to cardiac muscles, causing 
myocardial infarction. 
5 
1.2 Cholesterol homeostasis 
1.2.1 Liver as the main organ for cholesterol metabolism 
Liver produces over 50% of newly synthesized cholesterol, and is considered the 
single most important organ for the regulation of cholesterol metabolism in the body 
(Dietschy et al, 1993; Kruit et al, 2006; Repa & Mangelsdorf, 2000; Yao et al, 2007). 
It was estimated that there was about 100 grams of cholesterol in a 70-kg man and 
600-900 milligrams of cholesterol synthesized daily, whereas a mouse had a 
cholesterol pool of 50 milligrams and 3 milligrams of cholesterol was synthesized per 
day (Gylling & Miettinen, 1992; Gylling et al, 1994; Schwarz et al, 1998; Vuoristo & 
Miettinen, 1985). 
1.2.2 Regulatory sites of cholesterol metabolism 
Cholesterol balance is maintained in several regulatory points: intestinal 
cholesterol absorption, hepatic LDL cholesterol uptake, hepatic HDL-cholesterol 
uptake, hepatic cholesterol de novo synthesis, hepatic excretion into bile acids and 
cholesterol ester transfer between lipoprotein classes in the blood (Figure 1.3). 
1.2.2.1 Regulation of cholesterol absorption by acyl coenzyme A: cholesterol 
acyltransferase (ACAT) 
Cholesterol is uptaken and stored in cells in the form of cholesterol esters and the 
conversion is catalyzed by ACAT (Buhman et al, 2000; Chang et al, 1997) (Figure 
1.4). Two ACAT genes, designated as ACAT-1 and ACAT-2, have been identified in 
mammals (Chang et al, 2006; Meiner et al, 1996). ACAT-1 has been found in 
macrophages of atherosclerotic lesions, hepatic cells, adrenal glands, neurones and 
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Activity of acyl cholesterol: acyl transferase (ACAT) 
ACAT catalyzes the esterification between cholesterol and a fatty acid moiety. 
Adapted from Chen (2001). 
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mucosa and the liver (Burnett et al, 2005; Cases et al, 1998; Chang et al, 2000; 
Jimenez-Lopez et al, 2006; Lee et al, 1998; Miyazaki et al, 1998; Sakashita et al, 
2000; Sakashita et al, 2003). In a quantitative study, ACAT-1 mRNA was found to 
predominate over that of ACAT-2 in the liver, while ACAT-2 mRNA predominated 
over ACAT-1 in intestinal cells (Smith et al, 2004). 
ACAT-2 is an important factor in intestinal cholesterol absorption (Parini et al, 
2004; Repa et al, 2004; Willner et al, 2003). ACAT-2 deficiency had been reported to 
cause reduced intestinal cholesterol absorption in mice (Buhman et al, 2000). It has 
previously been shown by our laboratory that decrease in intestinal ACAT activity 
simultaneously occurred with increased fecal sterol excretion in hamsters fed 
conjugated linoleic acid (Yeung et al, 2000). Inhibition on ACAT activity by 
pharmaceutical inhibitors, e. g. NTE-122 and F-12511，has also been reported to 
associate with reduction on atherosclerosis incidence (Azuma et al, 2001; Rival et al, 
2002). 
There has been an increasing number of investigations on the possibility of 
achieving hypocholesterolemic and anti-atherosclerotic results from pharmaceuticals 
targeting at ACAT (Alegret et al, 2004; Chang et al, 2006). 
9 
1.2.2.2 Sterol regulatory element-binding protein 2 (SREBP-2) as a transcription 
factor for 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) 
and low-density lipoprotein receptor (LDLR) 
SREBP-2 is a protein belonging to the sterol regulatory element-binding protein 
family, which has been shown to play an important regulatory role in fatty acid and 
cholesterol synthesis (Eberle et al, 2004). 
There are three isofomis of SREBP found, namely SREBP-la, SREBP-lc and 
SREBP-2 (Weber et al, 2004). SREBP-la and SREBP-lc are encoded by the same 
gene, located on the human chromosome 17pll.2 (Hua et al, 1995b), while SREBP-2 
is encoded by a separate gene, located on 22ql3 (Miserez et al, 1997). SREBP-la and 
SREBP-lc are generated by alternative transcription start sites of the same gene and 
are responsible for the regulation of fatty acid metabolism (Liang et al, 2002), while 
SREBP-2 is involved in the regulation of cholesterol acquisition (Repa & 
Mangelsdorf, 2000). 
Structurally, SREBPs are basic helix-loop-helix-leucine zipper (bHLH-Zip) 
transcription factors, having a molecular size of about 125 kDa constituted by 1150 
amino acids (Weber et al, 2004). They are membrane-bound proteins found on the 
endoplasmic reticulum and nuclear envelope (Hua et al, 1995a). They become 
biologically active after activation by proteolytic cleavage (Eberle et al, 2004). Under 
appropriate conditions, SREBP cleavage-activating protein (SCAP) escort SREBP 
into the Golgi apparatus, where two proteases, namely site-1-protease (SIP) and 
site-2-protease (S2P) sequentially cleave the hydrophilic loop of SREBP, releasing the 
mature (nuclear) form SREBP into the cytosol (Matsuda et al, 2001; Sakai et al, 1998; 
Wang et al, 1994). 
SREBP-2 then binds to the sterol regulatory element on the chromosome, turning 
10 
up the expression of a number of cholesterol-generating genes (Sakakura et al, 2001), 
including HMGR and LDLR (Horton et al, 1998). A diagram explaining the activation 
process of SREBPs is shown in Figure 1.5. 
1.2.2.3 Roles ofLDLR 
LDLR is a trans-membrane, cell surface-residing and membrane-bound protein 
that belongs to the LDL-receptor related protein family (Hussain et al, 1999; May et 
al, 2007). Discovered and characterized by Brown and Goldstein (1986), this 
839-amino acid glycoprotein is responsible for receptor-mediated uptake and 
catabolism of LDL-cholesterol from the blood. LDLR is primarily expressed in the 
liver and adrenal gland (Kim et al, 1996). 
LDLR primarily recognizes ApoB-100, which is found on the surface of LDL 
particles (Brown & Goldstein, 1974; Goldstein & Brown, 1974). It also recognizes 
ApoE, which could be found on the beta-migrating form of VLDL and on certain 
intermediate and high density lipoproteins (Innerarity & Mahley，1978; Weisgraber et 
al, 1978). As the LDL particles bind to and complex with LDLR, clarithin-coated pits 
are formed and the complex enters the cell via endocytosis (Anderson, 1977a; 
Anderson, 1977b). The vesicles containing the complex are then transported to the 
endosome, where the LDL is released from LDLR in the low pH environment (Davis 
et al, 1987). LDLR is then recycled back to the cell surface again (Goldstein et al, 
1985). A schematic diagram on the process of LDL uptake from the blood via LDLR 
mediated endocytosis is shown in Figure 1.6. 
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Figure 1.5 
Activation of SREBPs through SREBP cleavage-activating protein (SCAP) 
escort and site-1-protease (SIP) and site-2-protease (S2P) cleavage. 
Nuclear SREBPs eventually enter the nuclear where they bind to the sterol 
regulatory element on the chromosome to activate gene expressions. Adapted 
from Bengoechea-Alonso & Maria (2007). 
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Schematic diagram on LDL endocytosis through LDLR 
Modified from Jeon ef al (2005). 
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Polymorphism or mutation in LDLR has been identified in certain individuals 
and been attributed to familial hypercholesterolemia, a genetic defect in LDLR in 
some individuals (Soutar & Naoumova, 2007; Widhalm et al, 2007). LDLR-mediated 
endocytosis is the main route of clearance of LDL cholesterol and cholesterol ester 
from the blood (Jones et al, 2007). The number of functional LDLR on cell surface 
has been shown to determine the rate of LDL catabolism (Hobbs et al, 1992). It has 
also been reported that when intracellular cholesterol decreases (Goldstein et al, 1985) 
or under the stimulation of certain factors (Liu et al, 1997)，nuclear form SREBP is 
released to the nucleus and activates the transcription of LDLR and HMGR (to be 
discussed in 1.2.2.4). Increased LDLR then promotes uptake of cholesterol from the 
LDL in blood and intracellular cholesterol balance is restored. 
In recent years, modulation of LDLR activity has been proposed as a strategy to 
reduce blood LDL cholesterol (Issandou, 2006). Increasing the number of LDLR on 
cell surface has been shown to be effective in promoting removal of LDL cholesterol 
from the blood and reducing blood LDL cholesterol level (de Medina et al, 2004; 
Defesche, 2004; Riidenko & Deisenhofer，2003). 
1.2.2.4 Rate limiting role of HMGR in cholesterol de novo synthesis 
Besides dietary intake, cholesterol could also be de novo synthesized from 
acetyl-CoA (Figure 1.7), in which reduction of 3-hydroxy-3-methylglmaryl coenzyme 
A (HMG CoA) into mevalonate by HMGR is the rate-limiting step along the pathway 
(Goldstein & Brown，1990). 
Being the rate-limiting enzyme in cholesterol synthsis, HMGR is one of the most 
highly regulated enzymes in nature (Goldstein & Brown，1990). Transcription of 
HMGR is regulated mainly through allosteric feedback regulation by cholesterol and 
14 
Acetyl CoA + Acctoacety< CoA 
.受- ->\Syfnh^ 
I HMGCOA 丨 © > 
： Meva^onate 
i Mevalonate-PP 
j ID V V、，， ^ 
丨 A / V . . — n t t n v l - P P -
_ > isopenlenyl Adenine 
I I (tRNA) 
I / W v � G e r a n y l - P P 刊 。 _ 
； I i [ t ——> Haem A 
！ FarnesyJ-PP — 、, ___ . 
I 、、一 I ‘ ——> Ubiquinone ！ I i t • > Famesylated Proleins 
I Squalene (Ras. lamm B, others) 
•！ j Y ^ l / t , > Steroid Hormones 
' � r t > t > Vitamin D 
C h o l f efol - ― � B 抽 Acids 
‘ L ~ > L.tpoprotoins 
、.… > 皿 ,Receptor 
Plasma LDL 
Figure 1.7 
The mevalonate pathway of cholesterol de novo synthesis 
HMGR acts as the rate-limiting enzyme in the pathway, while cholesterol itself 
acts as an allosteric inhibitor on HMGR by feedback regulation. 
(Adapted from Goldstein and Brown (1990)) 
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by SREBP-2. When intracellular cholesterol depletes, nuclear form SREBP-2 is 
released by proteolytic enzymes and enters the nucleus, where it activates 
transcription of HMGR (Horton et al, 1998). Increased HMGR promotes cholesterol 
synthesis to restore intracellular balance (Repa & Mangelsdorf, 2000). 
Inhibiting HMGR activity by pharmaceuticals is an established strategy to reduce 
blood LDL cholesterol, and statins are the first drugs approved for such purpose. 
Introduced in the U. S. since 1987, lovastatin was the first drug available for clinical 
use for hypercholesterolemia therapy (Bays, 2006). Statins have a similar structure as 
HMG-CoA, and hence they bind to the active site of HMGR, sterically inhibiting the 
binding of HMG-CoA to HMGR (Vaughan & Gotto，2004). Clinical trials reported 
that statins prescription reduced both total cholesterol (TC) and LDL-cholesterol 
concentrations in blood by 20-60% (Igel et al, 2002) while decreasing major coronary 
and major cerebrovascular events by 29% and 14% respectively (Thavendiranathan et 
al, 2006). 
1.2.2.5 Roles of liver-X-receptor-a (LXR-a) in cholesterol catabolism 
LXR, like SREBP-2, is a member in the nuclear receptor superfamily. There are 
two conserved subtypes of LXR identified, LXR-a and LXR-P. LXR-a is primarily 
expressed in the liver, adipose tissue and macrophages while LXR-p is almost 
ubiquitously expressed (Repa & Mangelsdorf，2000). LXR-a mainly functions as an 
activator of the transcription of cholesterol-7 a -hydroxylase, a key enzyme in 
cholesterol catabolism, while LXR-P is reported to promote cholesterol reverse 
transport from the peripheral to the liver (Lund et al, 2006). 
LXR-a is a sensor for oxysterols, which are the oxidation products of cholesterol 
(Janowski et al, 1996). LXR-a forms heterodimer with retinoid-X-receptor (RXR), 
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and under high intracellular oxysterol condition, which in turn implies high 
intracellular cholesterol, these oxysterols bind to LXR-a and the ligand-bound LXR-a 
becomes activated (Lehmanii et al, 1997). Activated LXR-a then binds to its response 
element, LXRE, in the promoter region of the cholesterol-7a-hydroxylase (CYP7A1) 
and initiates its transcription (Figure 1.8). 
The potential of LXR as target for hypercholesterolemia therapy has been studied 
extensively in recent years (Bruemmer & Law, 2005; Michael et al, 2005). Synthetic 
and natural LXR agonists (substances that bind to a receptor and activate its response) 
have been shown to activate LXR-dependent genes transcription and/or promote liver 
cholesterol efflux (Bramlett et al, 2003; Deng et al, 2006). Increased activated LXR 
activates CYP7A1 expression, which in turn increases bile acid synthesis. This 
promotes cholesterol output from the liver and depletes hepatic cholesterol content. 
Theoretically, this should stimulate hepatic LDLR activity and the ultimate outcome is 
increased clearance of LDL cholesterol from the blood, leading to 
hypocholesterolemic response. However, the data suggest that LXR may also induce 
fatty acid synthesis, and therefore use of LXR agonists could not be guaranteed to be 
anti-atherosclerotic at present (Millatt et al, 2003). 
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Activation of gene transcription by LXR 
Adapted from Millatt (2003). 
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1.2.2.6 Roles of CYP7A1 in catabolism of cholesterol into bile acids 
The liver is the only organ in the body capable of excreting excess cholesterol 
and its metabolites, thus maintaining cholesterol homeostasis (Vlahcevic et al, 1999). 
Approximately 50% of the excreted cholesterol is eliminated through conversion into 
bile acids which are eventually excreted in feces, while the remainder is mainly 
directly excreted into the feces through biliary canaliculi via a mechanism poorly 
understood. 
On one hand, conversion of cholesterol into bile acid excretes excess cholesterol 
out of the body. On the other hand, bile acid products act as an emulsifier and help 
lipids in the chyme turn into finer droplets, facilitating the digestion and absorption of 
fatty acids, sterols, fat-soluble vitamins and other hydrophobic nutrients. 
Bile acids may be synthesized via the classical (neutral) or the acidic (alternative) 
pathways. Human studies revealed that most (70-95%) of bile acids were synthesized 
via the classical pathway and the acidic pathway was comparatively inefficient (Swell 
et al, 1980). 
Cholesterol-7a-hydroxylase is the rate limiting enzyme in bile acid synthesis in 
the neutral pathway, which involves at least 15 enzymatic reactions in four organelles 
in the hepatocytes (Vlahcevic et al, 1992). Being a member of the cytochrome (GYP) 
family, cholesterol-7a-hydroxylase is also named CYP7A1. It is responsible for the 7a 
hydroxylation of cholesterol into 7a-hydroxycholesterol, the first and rate-limiting 
step in bile acid synthesis (Norlin & Wikvall, 2007; Pikuleva, 2006; Vlahcevic et al, 
1999). (Figure 1.9) 
Studies have shown that altering CYP7A1 activity could result in changes in 
blood cholesterol level (Hubacek & Bobkova，2006). Use of a bile acid sequestrant 
reduces body bile acid pool by 40%, activating CYP7A1 activity and hence increases 
19 
HO ‘“ ‘‘ OH 
Cholic Acid 
-'cHOtgSIgROL WAJ“ 
？ a-HYOftOXVl^ S!: GH " Y ^ 




Role of cholesterol-7a-hydroxylase in the classical pathway of bile acid 
synthesis 
Modified from Jelinek et a/.(1990). 
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bile acid output, and the ultimate result is a reduction of LDL-cholesterol by 15-26% 
(Insull, 2006). In cultured cells, overexpression of CYP7A1 by molecular techniques 
in HepG2 and PHH cells significantly increased bile acid synthesis through the 
classical pathway (Pandak et al, 2001). 
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1.2.2.7 Roles of cholesterol ester transfer protein (CETP) in maintaining 
cholesterol distribution in blood 
CETP is a 476-amino acid glycoprotein that is mainly secreted by the liver and 
adipose tissue into the circulating blood. Bound mainly to HDL, CETP catalyzes the 
transfer of cholesterol ester from HDL to apoB-containing lipoproteins (e.g. LDL, 
VLDL, VLDL remnants) and that of triglyceride from apoB-containing lipoproteins to 
HDL in the blood (Le Goff et al, 2004). Since HDL mainly transports cholesterol 
from the peripheral to the liver for catabolism via scavenger receptor route in reverse 
cholesterol transport (RCT), reduction in HDL-cholesterol by CETP decreases direct 
RCT (Shah, 2007) and may increase the risk of atherosclerosis. 
Besides lipid transfer, CETP also modifies the size of circulating lipoproteins 
into small, dense ones (Chung et al., 1998). Present epidemiological data suggest that 
reduced LDL size is associated with a higher risk of CHD (Gardner et al., 1996; 
Lamarche et al, 1997; Stampfer et al., 1996). These further suggest that CETP 
activity is pro-atherosclerotic. 
However, there are also opinions that CETP carries anti-atherosclerotic property 
through its enhancement in indirect RCT. Redistribution of cholesterol ester from 
HDL into LDL allows transfer of cholesterol ester to the liver via LDLR (Figure 1.10). 
In species having a high expression level of CETP like rabbit, this route contributes 
about 70% of cholesterol uptake from HDL (Barter et al., 2003; Goldberg et al., 
1991). 
However, in human, the reduction of direct RCT by CETP seems not be 
neutralized by its increase in indirect RCT. Patients having mutation in CETP genes 
were found to have higher HDL-cholesterol levels than normal subjects (Inazu et al, 
1990). A recent human trial found out that CETP inhibition by Torcetrapib, a CETP 
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inhibitor, increased HDL-cholesterol by 60% while decreasing LDL-cholesterol by 
20%, yet not affecting atherosclerosis progression (Nissen et al., 2007). Ansell and 
Hobbs (2006) reviewed 30 reports about vaccine and pharmacological CETP 
inhibition and concluded that pharmacological CETP inhibitors generated a more 
consistent increase in HDL-cholesterol. Nonetheless, at least seven classes of CETP 
inhibitors are now under development and CETP inhibition is now a new target in the 
treatment of dyslipidemia (Shah, 2007). 
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Roles of CETP in redistributing lipids in the blood. Key: TRL: triglyceride-rich 
lipoprotein 
(Adapted from Barter (2003)) 
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Chapter 2 
Effect of Octadecaenoic Acids on 
Blood Cholesterol in Hamsters 
2.1 Introduction 
2.1.1 Effects of polyunsaturated fatty acids (PUFAs) on blood cholesterol 
Traditionally, PUFAs are regarded as protective factors for CHD (Grundy et al, 
1982; Krauss et al, 2000; Kris-Etherton et al, 2002), while saturated fatty acids are 
regarded as inducing factors (Boniface & Tefft, 2002; Esrey et al, 1996; Goldbourt et 
al, 1993; Kushi et al, 1985). However, human epidemiological studies reported 
inconsistent effects of PUFAs on blood cholesterol and risks of CHD. Mensink et al 
(2003)，Oh et al (2005), Shekelle et al (1981), Goldbourt et al (1993) and Hu et al 
(1997) found an inverse association between PUFAs consumption and risk of CHD, 
while some others found no association (Ascherio et al, 1996; Garcia-Palmieri et al, 
1980; Gordon et al, 1981; Kromhout & de Lezenne, 1984; Morris et al, 1977). 
Investigations in individual PUFAs, however, generated more consistent results. 
Longer-chain Cl)-3 PUFAs from fish oil, including eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), reduced CHD risk (de Lorgeril et al, 1999; Lichtenstein, 
2006). These data suggest that the specific effects of these individual fatty acids on 
the cardiovascular system deserve more investigation. 
2.1.2 Differential effects of 18-C PUFAs on lowering blood cholesterol in vivo 
The two essential 18-C PUFAs, namely linoleic acid (LA) and a -linolenic acid 
(LN), are the parent compounds of other 6l)-6 and 6J-3 PUFAs respectively. In recent 
years, the conjugated forms of these fatty acids have also received scientific attention 
(Fischer-Posovszky et al, 2007; Koba et al, 2007; Ledoux et al, 2007; Purushotham et 
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al, 2007; Ribot et al, 2007). It had been shown in our lab that both LA and conjugated 
linoleic acid (CLA) decreased blood cholesterol in hamsters, but CLA reduced 
intestinal ACAT activity while LA did not (Yeung et al, 2000). In contrast, LN but not 
conjugated linolenic acid (CLN) was hypocholesterolemic in hamsters (Yang et al, 
2005). 
2.1.3 Structures, metabolism and conjugation of octadecaenoic acids (ODA) 
LA and CLA are 18-C PUFAs of similar structures that cannot be synthesized in 
humans. Both LA and CLA can be desaturated and elongated into longer chain PUFAs. 
LA can be converted into arachidonic acid by A-6 desaturase and elongase while LN 
can be converted into EPA and DHA by A-3 desaturase and elongase. 
The two double bonds in LA are unconjugated while CLA is a group of 
positional and geometric isomers with the two double bonds being in conjugation. LN 
is a more highly unsaturated form of 18-C fatty acid and has three unconjugated 
double bonds, while CLN, a group of isomers of LN, have three conjugated double 
bonds. The structures of LA, CLA, LN and CLN are shown in Figure 2.1. 
2.1.4 Objectives 
Previous studies demonstrated that four structurally similar 18-C PUFAs, namely 
LA, CLA, LN and CLN affected blood cholesterol and cholesterol metabolism 
differently (Yang et al, 2005; Yeung et al, 2000). However, the underlying mechanism 
is not established. The present study consisted of two experiements. Experiment 1 was 
conducted to investigate the effect of LA, CLA, LN and CLN on blood cholesterol 
and five cholesterol-regulating proteins, namely, SREBP-2, HMGR, LDLR, LXR and 
CYP7A1 in hamsters. Experiment 2 was conducted to investigate the effect of LA, 





Schematic diagram showing the simplified structures of: 1，linoleic acid (LA); 2, 
conjugated linoleic acid (CLA); 3’ linolenic acid (LN); 4, conjugated linolenic 
acid (CLN). 
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2.2 Experiment 1 
2.2.1 Materials and methods 
2.2.1.1 Experimental fatty acids 
LA and CLA were purchased from Sigma (St Louis, MO, USA) and Larodan 
Fine Chemicals AB (Malmo, Sweden) respectively, while LN and CLN were 
extracted and purified from flaxseed and tung seed, respectively, as previously 
described by Yang et al (2005) with slight modifications. The CLA was a 1:1 mixture 
of c9, t i l and tlO, c l2 CLA isomers. 
2.2.1.1.1 Isolation of LN from flaxseed 
Flaxseeds were crushed in a coffee bean grinder and were soaked in n-hexane for 
90 minutes with continuous stirring. Flaxseed oil was obtained after removal of 
hexane in a rotary evaporator. 130 g of the oil was saponified in 2 L 0.3 M KOH in 
methanol at 90"C under a gentle nitrogen stream for 2 hours. After acidification of 1 
M H2SO4 to pH 1.0，LN in the crude fatty acid mixture was isolated by a three-step 
crystallization process. The mixture was dissolved in three volumes of ethanol and 
placed in 4°C for 24 hours and the crystals were removed by suction filtration. The 
process was repeated at -20°C and -50°C in a fatty acids-ethanol ratio of 1:10 (v/v). 
The final purity of LN was about 80 %. 
2.2.1.1.2 Isolation of CLN from tung seed 
Tung seeds were ground and soaked in n-hexane. Tung oil was saponified 
similarly as flaxseed oil in 2.2.1.1.1. The crude fatty acid mixture was placed in 4 � C 
for 8 hours and the CLN-containing yellowish needle-shaped crystals were filtered 
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and collected. Purity of CLN in these crystals was about 80%. 
2.2.1.2 Animals 
Male adult Golden Syrian hamsters {Mesocricetus auratus, n=50, 113+6g) were 
obtained from the Laboratory Animal Services Centre, The Chinese University of 
Hong Kong. They were randomly divided into five groups (n=10) and housed (2 per 
cage) in wire-bottomed cages at 23°C in a 12-hour light-dark cycle. 
Before the experiment, all the animals were allowed to stabilize by being fed a 
high fat high cholesterol diet (control diet). From week 0 to week 6, one group were 
continued to feed on the control diet and the other four groups were fed a similar diet 
except that they were respectively supplemented with 2% of LA, CLA, LN and CLN. 
During the study, food was given daily and any uneaten food was discarded. The 
amount of food consumed was measured each day. The animals had free access to 
food and distilled water and were weighed weekly. Feces of the animals were saved 
and collected every week. 
Blood (1 niL) was bled from the retro-orbital sinus into a heparinized capillary 
tube at the end of weeks 0，3 and 6 after food deprivation for 16 hours. The blood was 
centrifuged at 3000rpm for 10 minutes and the plasma was collected and stored at -20 
until analysis. 
After the last blood sample collection at the end of week 6, the hamsters were 
kept for three more days to allow for recovery. They were then sacrificed by nitrogen 
suffocation with their food available (full stomach) at midnight. Blood was collected 
from abdominal artery into a vacuum heparinized tube, centrifuged at 800 x g at 10 
minutes and the plasma was collected and stored at -20°C until analysis. The liver, 
heart, kidney, adipose tissue (perirenal and epididymal pads) were removed, washed 
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in saline, weighed, frozen in liquid nitrogen and stored at -80�C until analysis. 
2.2.1.3 Diets 
The control diet was prepared by mixing the following ingredients in proportion 
(g/kg diet): cornstarch, 488; casein, 242; lard, 100; sucrose, 119; mineral mix AIN-76, 
40; viamin mix AIN-76A, 20; DL-methionine, 1; cholesterol, 1. The four 
experimental diets were prepared by adding 2% by weight of the fatty acids into the 
control diet respectively. The powered diets were mixed with a gelatin solution (20g/L) 
in a ratio of 200g diet per liter of solition (Table 1). Once the gelatin had set, the diets 
were cut into pieces of approximately 10 g cubes and stored frozen at -20°C. 
2.2.1.4 Plasma lipid measurements 
Plasma total cholesterol (TC) and triglyceride (TG) were measured by 
commercial enzymatic kits from Infinity (Waltham, MA, U. S. A.) and Stanbio 
Laboratories (Boeme, TX, U. S. A.) respectively according to the manufacturer's 
instructions. For measurement of plasma HDL-cholesterol, LDL and VLDL were first 
precipitated with phosphotungstic acid and magnesium chloride using a commerical 
kit (Stanbio) and HDL-cholesterol in the supernatant was determined similarly as did 
total cholesterol. Non-HDL cholesterol was calculated by deducting HDL-cholesterol 
from TC. 
2.2.1.5 Plasma CETP activity measurement 
Plasma CETP activity of the hamsters was measured by a commercial kit 
(Amersham Pharmacia Biosciences, Piscataway, NJ, U. S. A.) according to the 
manufacturer's instructions with slight modifications. In brief, lOjil of ^H-HDL, 
biotinylated LDL and assay buffer were mixed with 5|il of hamster plasma samples 
and the mixture was incubated at 37°C for 16 hours. After that, a stop solution 
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containing SPA-beads that specifically bound to biotinylated LDL was added to detect 
[^H] radiation emitted from LDL. The reaction mixture was read on a Beckman 
LS6500 scintillation counter (Beckman, Fullerton, CA, U. S. A.). 
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Table 1 Compositions for the diets of the five groups of hamsters (g/ kg diet) 
Control LA CLA LN C L N ~ 
Cornstarch 478 478 478 
Casein 200 196 196 196 196 
Sucrose 150 147 147 147 147 
Mineral mix 40 39 39 39 39 
(AIN-76) 
Vitamin mix 20 20 20 20 20 
(AIN-76A) 
d-methionine 1 1 1 1 1 
Cholesterol 1 1 1 1 1 
Lard 100 98 98 98 98 
LA 0 20 0 0 0 
CLA 0 0 20 0 0 
LN 0 0 0 20 0 
CLN 0 0 0 0 20 













































































































































































































































































































































2.2.1.6 Measurement of liver SREBP-2, LDLR, HMGR and CYP7A1 protein 
abundance by Western blotting 
Hepatic protein was extracted according to the method described by Vaziri et al 
(1996) with some modifications. In brief, frozen liver was ground in a homogenizing 
buffer containing 20mM Tris-HCl (pH 7.5)，2mM MgCb, 0.2M sucrose and 
Complete® protease inhibitor cocktail (Roche, Mannheim, Germany). The extract 
was centrifuged at 12,000 g for 15 minutes at 4 °C and the supernatant was collected 
and considered as the 'total protein'. A portion of the total protein was then 
centrifuged at 35,000 rpm for 60 minutes at 4 The supernatant was removed and 
the pellet was resuspended in the homogenizing buffer described above and 
considered as 'membrane protein'. Protein concentration of two fractions was 
determined using a protein concentration assay kit according to the manufacturer's 
instructions (Bio-Rad，Hercules, CA, U. S. A.). 
For the measurement of LDLR, CYP7A1 and HMGR, 100|ig of the membrane 
protein was size-fractionated by 7 % SDS-PAGE at 120V for two hours. The proteins 
were then transferred to a Hybond-P PVDF membrane (Amersham Pharmacia 
Biosciences). The membrane was incubated for one hour in blocking solution (5% 
nonfat milk in IX TBST) at 4 °C and then overnight in the same solution containing 
1:300 anti-LDL receptor antibody (Santa Cruz Biotechnology, Inc., California, U. S. 
A.) or 1:500 anti-HMGR (Upstate USA Inc., Lake Placid, NY, USA) and 1:200 
anti-CYP7Al (Santa Cruz Biotechnology, California, U. S. A.) whichever appropriate. 
The membrane was then washed three times for 15 minutes in 1 x TBS and 0.1% 
Tween-20 and was then incubated for one hour at 4 in diluted (1:3000) horseradish 
peroxidase-Iinked rabbit anti-goat IgG (Zymed Laboratories Inc., San Francisco, CA, 
U. S. A.) or donkey anti-rabbit IgG (Santa Cruz Biotechnology). The washes were 
repeated before the membranes were developed with ECL enhanced 
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chemiluminescence agent (Amersham Life Science) and subjected to autoradiography 
for one to five minutes on SuperiLY" medical X-ray film (Fuji, Tokyo，Japan). 
Densitometry was quantified using the computer software Photoshop® (Adobe 
Systems Inc, CA, U. S. A). 
For SREBP-2, lOOjxg of the membrane protein and 50^g of the total protein 
aliquots were mixed and simultaneously size-fractionated on 7% SDS-PAGE at 120V 
for two hours. The remaining procedures were the same as described above except 
1:300 anti-SREBP-2 antibody (Santa Cruz Biotechnology) was used as primary 
antibody. 
2.2.1.7 Measurement of hepatic SREBP-2, LDLR, HMGR, LXR, CYP7A1, CETP, 
SR-Bl and LCAT mRNA by real time PGR 
2.2.1.7.1 Extraction of mRNA 
Hepatic mRNA was extracted and isolated using the commercial extraction agent 
Trizol® (Invitrogen，Carslbad，CA, U. S. A.) according to the manufacturer's 
instructions. In brief, 3 mL of Trizol was added into approximately 300 mg of liver 
sample and the sample was homogenized with a tissue tearor (Biospec, OK, U. S, A.) 
on ice. The homogenate was then centrifuged at 4000 x g for 25 minutes at 4 The 
supernatant was then transferred to a new vial and allowed to stand at temperature for 
5 minutes. Chloroform was added to the vial in a homogenate: chloroform ratio of 5:1 
and the vial was then vortexed for 15 seconds. After a 3-minute standing at room 
temperature, the vial was centrifuged at 11900 x g for 15 minutes at 4 The 
RNA-containing upper aqueous layer was transferred to a new vial and isopropyl 
alcohol was added in a homogenate: isopropyl alcohol ratio of 2:1. After gently 
mixing 3 times, the content was allowed to stand for 10 minutes at room temperature 
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and then centrifuged at 11900 x g for 10 minutes at 4 The supernatant was 
discarded and the RNA pellet was resuspended with 1 mL of 75% (v/v) ethanol. After 
vortexing and centrifugation at 7500 x g for 5 minutes at 4 the ethanol was 
removed and the RNA pellet was air dried. After dissolution in 30 |LIL DEPC-treated 
water (0.1% (v/v) of diethyl pyrocarbonate (DEPC) solution in distilled water stirred 
overnight at room temperature and then autoclaved), the samples were stored at -80°C 
until analysis. 
2.2.1.7.2 Complementary DNA synthesis 
Total RNA was converted to complementary DNA (cDNA) by reverse 
transcriptase (Applied Biosystems, Foster City, CA, U. S. A.). 4|ig total RNA was 
mixed with 1 |il of 50 jiM oligo (dT) 25，1 jul of 3 |ig/|il random primers, 2 |il of 10 
mM dNTP mixture (all are purchased from Applied Biosystems) and the volume was 
adjusted to 12 jul with DEPC-treated water. The mixture was incubated at 65°C for 5 
minutes and then chilled on ice. 4 of 5X M-MuLV reverse transcriptase reaction 
buffer, 1 jil of 50mM MgC12, 1 )il M-MuLV reverse transcriptase RNase H minus 
(250 U/^il) (all are from Applied Biosystems) and 2 \x\ DEPC-treated water were 
added. Reverse transcription was carried out in thermocycler (Gene Amp ® PGR 
system 9700, Applied Biosystems), with programme set as initiation for 10 minutes at 
25°C, followed by 50°C incubation for 90 minutes and 85°C for another 5 minutes. 
The cDNA synthesized was collected and stored at -20°C. 
2.2.1.7.3 Real-time polymerase chain reaction (PGR) anaylsis 
Real-time PCR analysis was carried out on a Fast Real-time PCR System 7500 
(Applied Biosystems) installed with the Sequence Detection Software version 
36 
1.3.1.21 (Applied Biosystems). Five genes studied were: SREBP-2 (GenBank 
accession number U12330)，LDLR (GenBank accession number Ml3877), HMGR 
(GenBank accession number X00494), LXR (GenBank accession number 
NM—005693)，CYP7A1 (GenBank accession number L04690) and CETP (GenBank 
accession number M63992). The expressions of target genes were normalized with 
that of GAPDH (GenBank accession number DQ403055), a housekeeping gene being 
used as an internal control. The primers and probes were manufactured by Applied 
Biosystems. 
In a PGR run, a 20 |il universal master mixture (Applied Biosystems), containing 
10 |Lil of 2X TaqMan® Fast Universal PGR Master Mix, 2 |il diluted cDNA, 1 jul of 
20x Assays-on-Demand Gene Expression Products (consisting of forward and reverse 
PCR primers, and 1 FAM dye-labeled TaqMan MGB probe) and 7 |li1 autoclaved 
distilled water, was first prepared on ice. The reaction mixture was then subject to 
thermal cycling conditioned follows: heating up from room temperature to 95 °C in 
20 seconds, followed by 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. 
Fluorescence measurements were recorded during each annealing step. At the end of 
each PCR run, the data were analyzed by the Sequence Detection Software version 
1.3.1.21 and amplification plots were obtained. 
Threshold cycle (Ct) values were exported into a Microsoft Excel worksheet for 
the calculation of gene expression according to the AACt method (Applied 
Biosystems). Levels of gene expressions in the treatment groups were presented as a 
ratio of treatment: control group. 
2.2.1.8 Determination of cholesterol in liver 
Cholesterol content in the liver were determined by a method described by 
Chan et al (1999). Briefly, 1 mg of stigmastanol (as internal standard) was added into 
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about 300 mg of liver sample. 15 mL of methanol-chloroform mixture (2:1, v/v) were 
used to extract lipids from the tissue together with 5 mL of saline, and the 
chloroform-methanol phase was saved and evaporated to dryness under a nitrogen 
stream. The lipids were then mildly saponified with 6 mL of m l M NaOH in 90% 
ethanol at 90°C for 1 hour, followed by the extraction of non-saponified substances 
(including cholesterol) by 6mL of cyclohexane together with 1 mL of water. The 
extracted substances were then converted into their trimethylsilyl-ether derivatives by 
a commercial trimethylsilyl reagent (dry pyridine-hexamethyldisilazane, 9: 3: 1, v/v/v, 
Sil-A Reagent, Sigma) at 60°C for 1 hour. After flushing with nitrogen to dryness, the 
cholesterol trimethylsilyl-derivatives resuspended in 500 jiL of n-hexane and 
transferred into GC-vials and were analyzed in a fused silica capillary column 
(SACtm-5，30m X 0.25mm internal diameter, Supelco, Inc., Bellefonte, PA, USA) in a 
Shimadzu GC-14B GLC equipped with a flame ionization detector (Shimadzu, Tokyo, 
Japan). The column temperature was set at 285°C and held for 25 minutes. Helium 
was used as the carrier gas at a head pressure of 150 kPa. Amount of cholesterol in the 
tissue was calculated as a ratio of internal standard added. 
2.2.1.9 Determination of fecal neutral and acidic sterols 
Neutral and acidic sterols in the feces were determined by a method described by 
Czubayko (1991) with slight modification. The feces collected were first isolated and 
dried in lyophilizer, weighed and ground into powder by a coffee bean mill. 
Stigmasterol (0.5 mg, Sigma) in 200 juL of chloroform was added into a methylation 
tube as an internal standard for neutral sterols and dried down by a gentle stream of 
nitrogen. About 300 mg of lyophilized fecal sample was weighed into the methylation 
tube together with 0.5 mg hyodeoxycholic acid in 200 mL IN NaOH in 90% EtOH 
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being added as an internal standard for acidic sterols. The samples were then mildly 
hydrolyzed in 8 mL IN NaOH in 90% EtOH at 90°C for 1 hour. Then, 8 mL of 
cyclohexane together with 1 mL of water were added to extract of total neutral sterols. 
The methylation tubes were centrifuged to separate the neutral sterol-containing upper 
cyclohexane phase and the acidic sterol-containing lower aqueous phase. The two 
phases were separately analyzed as described as below. 
2.2.1.9.1 Determination of fecal neutral sterols 
The cyclohexane phase was transferred into a new methylation tube and 
evaporated to dryness under a gentle nitrogen stream. The sterols were converted into 
their trimethylsilyl derivatives using a commercial trimethylsilyl reagent (dry 
pyridine-hexamethyldisilazane, 9: 3: 1，v/v/v, Sil-A Reagent, Sigma) at 60°C for 1 
hour. After drying by a nitrogen stream, the sterol derivatives were dissolved in 
400|iL of n-hexane and transferred into a GC vial and read in a fused silica capillary 
column (SAC™-5, 30 m x 0.25 mm internal diameter, Supelco, Bellefonte, PA, U. S. 
A.) in a Shimadzu GC-14B GC equipped with a flame-ionization detector (Shimadzu, 
Kyoto, Japan). Helium was used as the carrier gas at head pressure 150 kPa and the 
programme was maintained at 285°C for 30 minutes. Each neutral sterol (coprostanol, 
coprostanone, cholesterol and dihydrocholesterol) was identified by comparing their 
retention time with that of authentic standards (Sigma). A typical cliromatogram is 


















































































































































































2.2.1.9.2 Determination of fecal acidic sterols 
The bottom aqueous layer described in 2.2.8 was saved for determination of 
acidic sterol content. 1 mL of 10 N NaOH was added and the mixture was heated at 
120�C for 3 hours. 3 mL of water and 1 mL of 25% HCl were then added and the 
acidic sterols were extracted twice using 7 mL of diethyl ether. The ether phases were 
pooled and dried under a gentle stream of nitrogen. Then, 2 mL of methanol, 2 mL of 
2,2-dimethoxypropane and 40 |iL of 37% HCl were added and the mixture was 
allowed to stand overnight, followed by evaporation to dryness under nitrogen. 300 
|iL of a commercial trimethylsilyl reagent (dry pyridine-hexamethyldisilazane, 9: 3: 1， 
v/v/v, Sil-A Reagent, Sigma) were added and the acidic sterols were converted into 
their trimethylsilyl derivatives at 60�C for 1 hour. The solvent was dried down under a 
gentle nitrogen stream and dissolved in 300 |iL of hexane. After centrifugation, the 
supernatant was transferred into a GC vial and analyzed on a fused silica capillary 
column (SAC™-5, 30 m x 0.25 mm internal diameter, Supelco) in a Shimadzu 
GC-14B GC equipped with a flame-ionization detector (Shimadzu). Helium was used 
as the carrier gas at head pressure 150 kPa and the programme was set from 230�C to 
280°C at a rate of PC/ min. Retention time of each acidic sterol (lithocholic acid, 
deoxycholic acid, chenodeoxycholic acid and cholic acid) was compared with that of 
























































































































































































Results were presented as means 士 standard deviation (S.D.). Where applicable, 
statistical significance of differences between groups was assessed by one-way 
analysis of variance (ANOVA) followed by Student's "test, or Pearson's correlation 
coefficient, using Prism® (Graphpad software, Inc., CA, U. S. A.). Differences 
between groups were considered significant when 户<0.05. 
43 
2.2.2ResuIts 
2.2.2.1 Growth and food intake 
The body weight and food intake are shown in Table 2,3. No significant 
difference in amount of food intake or body weight was observed in the control, LA, 
CLA, LN or CLN hamsters. 
2.2.2.2 Organ weights 
Weights of liver, adipose tissues (epididymal and perirenal pads), kidneys and 
hearts of the hamsters are shown in Table 2.4. Weights of the liver in groups fed CLA 
and CLN were significantly higher than those of the hamsters fed the control diet. 
Weights of epididymal and perirenal adipose pads of hamsters fed CLA were 
significantly lower than those fed the control diet. Kidneys of hamsters fed LN 
weighed significantly higher than those fed the control diet. No significant difference 
in weights was observed in other organs. 
2.2.2.3 Effects ofODA on serum TC, TG and HDL-C 
Serum TC in hamsters fed LA, CLA and LN were significantly lower than that of 
the control, but TC in CLN group was not significantly different from that in the 
control. To be specific, TC of LA, CLA and LN were 15.0%, 24.2% and 24.2% lower 
than the control. There was no significant difference in TC among LA, CLA and LN 
(Table 2.5). Serum HDL-C was not significantly different among the groups. 
Non-HDL-C/HDL-C ratio in CLA and LN groups, but not that in LA and CLN was 
significantly lower than the control. No significant difference in serum TG was 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.2.2.4 Effect of ODA on liver cholesterol 
Liver cholesterol levels in hamsters fed LA, CLA, LN and CLN were all 
significantly lower than that in the control. Liver cholesterol was reduced the most in 
the CLA-fed group (65.8% reduction)，followed by that of LN (49.8%), CLN (36.6%) 
and LA (22.8%) (Figure 2.3). 
When LA was compared with CLA, hamsters fed CLA had their liver cholesterol 
significantly lower than those fed LA. However, for LN and CLN, liver cholesterol of 
hamsters fed CLN was significantly higher than those fed LN. 
2.2.2.5 Effect of ODA on fecal neutral sterol output 
Concentration of neutral sterol in the feces of the hamsters at week 6 is shown in 
Figure 2. 4. Total neutral sterol content in the feces of hamsters fed CLA and LN but 
not LA and CLN was significantly higher than that in the control. Specifically, CLA 
increased fecal neutral sterol content by 53.7%. LN increased it by 21.7% while CLN 
had no significant effect on fecal neutral sterol content. 
2.2.2.6 Effect of ODA on fecal acidic sterol output 
Concentration of fecal acidic sterol output is shown in Figure 2.5. There was no 
significant difference in acidic sterol concentration in hamsters with or without ODA 
feeding. 
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Figure 2.3 
Effect of octadecaenoic acid (ODA) feeding on the liver cholesterol level in 
hamsters. 
Values are expressed as means 土 S.D. (n=10). Bars with different letters (a, b, 
c，d and e) are significantly different at p<0.05. 
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Figure 2.4 
Effect of octadecaenoic acid (ODA) feeding on fecal neutral sterol output. 
Values are expressed as means 土 S.D. (n=10). Bars with different letters (a, b 
and c) are significantly different at p<0.05. 
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Control LA CLA LN CLN 
Group 
Figure 2.5 
Effect of octadecaenoic acid (ODA) feeding on fecal acidic sterol output. 
Values are expressed as means 土 S.D. (n=10). 
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2.2.2.7 Effect of ODA on cholesterol balance in hamsters 
Total intake of cholesterol by the hamsters was compared with its excretion in 
neutral and acidic sterols (Table 2.6). Cholesterol retention/ cholesterol intake (%) in 
the hamsters was reduced by LA and CLA but not LN and CLN. 
2.2.2.8 Effect of ODA on plasma CETP activity 
Plasma CETP acitivity of the hamsters is shown on Figure 2.6. There was no 
significant difference in CETP activity among the control group hamsters and those 
fed ODA. 
2.2.2.9 Correlation between blood TC and liver cholesterol 
As shown in Figure 2.7，liver cholesterol level was significantly and positively 
correlated with serum total cholesterol in hamsters of all groups (r=0.388, p<0,01). 
2.2.2.10 Correlation between blood HDL-C and liver cholesterol 
As shown in Figure 2.8，liver cholesterol level had no significant association 
with serum HDL-cholesterol in hamsters of all groups (r=0.031, p>0.05). 
2.2.2.11 Correlation between blood nHDL/HDL ratio and liver cholesterol 
As shown in Figure 2.9，liver cholesterol level significantly and positively 
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Figure 2.6 
Plasma CETP activity in hamsters fed the control and octadecaenoic acid 
(ODA)-supplemented diets. Data are normalized so that CETP activity of the 
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Figure 2. 7 
Correlation between serum cholesterol and liver cholesterol levels, n=50, 
Pearson r=0.3883’ p<0.01 
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Figure 2.9 
Correlation between serum non-HDL-cholesterol/ HDL-cholesterol ratio and 
liver cholesterol level, n=50, Pearson「=0.455，p<0.01. 
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2.2.2.12 Effect of ODA on liver SREBP-2 immunoreactive mass 
Liver SREBP-2 immunoreactive mass as revealed by Western Blot analysis is 
shown in Figure 2.10. There was no significant difference in SREBP-2 
immunoreactive mass between the control and the ODA supplemented hamsters. 
2.2.2.13 Effect of ODA on liver LDLR immunoreactive mass 
Liver LDLR immunoreactive mass as revealed by Western Blot analysis is 
shown in Figure 2.11. There was no significant difference in LDLR immunoreactive 
mass between the control and the ODA supplemented hamsters. 
2.2.2.14 Effect of ODA on liver HMGR immunoreactive mass 
Liver HMGR immunoreactive mass as revealed by Western Blot analysis is 
shown in Figure 2.12 There was no significant difference in HMGR immunoreactive 
mass between the control and the ODA supplemented hamsters. 
2.2.2.15 Effect of ODA on liver LXR immunoreactive mass 
Liver LXR immunoreactive mass as revealed by Western Blot analysis is shown 
in Figure 2.13. There was no significant difference in LXR immunoreactive mass 
between the control and the ODA supplemented hamsters. 
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F i g u r e 2 .10 
Relative abundance of hepatic sterol regulatory element-binding protein-2 
(SREBP-2) immunoreactive mass as determined by Western Blot anaylsis. 
Data are normalized with (3-tubulin so that value of the control group is 
regarded as 1.0. Values are expressed as means 土 S.D. (n=10). 
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F i g u r e 2.11 
Relative abundance of hepatic low-density lipoprotein receptor (LDLR) 
immunoreactive mass as determined by Western Blot anaylsis. Data are 
normalized with p-tubulin so that value of the control group is regarded as 1.0. 
Values are expressed as means 土 S.D. (n=10). 
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F i g u r e 2 .12 
Relative abundance of hepatic 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMGR) immunoreactive mass as determined by Western Blot 
anaylsis. Data are normalized with (3-tubulin so that value of the control group 
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Figure 2.13 
Relative abundance of hepatic liver-X-receptor (LXR) immunoreactive mass as 
determined by Western Blot anaylsis. Data are normalized with p-tubulin so 
that value of the control group is regarded as 1.0. Values are expressed as 
means 土 S.D. (n=10). 
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2.2.2.16 Effect of ODA on liver CYP7A1 immunoreactive mass 
Liver CYP7A1 immunoreactive mass as revealed by Western Blot analysis is shown 
in Figure 2.14. There was no significant difference in CYP7A1 immunoreactive mass 
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Relative abundance of hepatic cholesterol 7a-hydroxylase (CYP7A1) 
immunoreactive mass as determined by Western Blot anaylsis. Data are 
normalized with |3-tubulin so that value of the control group is regarded as 1.0. 
Values are expressed as means 士 S.D. (n=10). 
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2.2.2.17 Effects of ODA on hepatic CETP mRNA 
Hepatic CETP mRNA abundance is shown in Fig.2.15. No significant difference 
was observed in mRNA abundance among the control and ODA treated groups. 
2.2.2.18 Effects of ODA on hepatic LDLR mRNA 
Hepatic LDLR mRNA abundance is shown in Fig.2.16. No significant difference 
was observed in mRNA abundance among the control and ODA treated groups. 
2.2.2.19 Effects of ODA on hepatic LXR mRNA 
Hepatic LXR mRNA abundance is shown in Fig.2.17. No significant difference 
was observed in mRNA abundance among the control and ODA treated groups. 
2.2.2.20 Effects of ODA on hepatic CYP7A1 mRNA 
Hepatic CYP7A1 mRNA abundance is shown in Fig.2.18. No significant 
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Fig 2.15 
Hepatic cholesterol ester transfer protein (CETP) mRNA abundance in 
hamsters fed octadecaenoic acid (ODA). Data are normalized with GAPDH 
RNA so that value of the control group is regarded as 1.0. Values are 
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Fig 2.16 
Hepatic low-density lipoprotein receptor (LDLR) mRNA abundance in hamsters 
fed octadecaenoic acid (ODA). Data are normalized with GAPDH RNA so that 
value of the control group is regarded as 1.0. Values are expressed as means 
士 S.D. (n=10). 
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Fig 2.17 
Hepatic liver-X-receptor (LXR) mRNA abundance in hamsters fed 
octadecaenoic acid (ODA). Data are normalized with GAPDH RNA so that 
value of the control group is regarded as 1.0. Values are expressed as means 
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Fig 2.18 
Hepatic cholesterol 7a-hydroxylase (CYP7A1) mRNA abundance in hamsters 
fed octadecaenoic acid (ODA). Data are normalized with GAPDH RNA so that 
value of the control group is regarded as 1.0. Values are expressed as means 
土 S.D. (n=10). 
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2.3 Experiment 2 
2.3.1 Materials and Methods 
2.3.1.1 Experimental diets 
The fatty acids used in experiment 2 had the same sources as those used in 
experiment 1 (section 2.2.1.1). The five diets were similarly prepared as described in 
section 2.2.1.3. 
2.3.1.2 Animals 
Male adult Golden Syrian hamsters {Mesocricetus auratus, n=45, 113±7g) were 
randomly divided into five groups (n=9), fed, housed (2 or 3 per cage), bled and killed 
similarly as described in section 2.2.1.2. The liver, heart, kidney, adipose tissue 
(perirenal and epididymal pads) were removed, washed in saline, weighed, flash 
frozen in liquid nitrogen and stored at -80°C until analysis. The small intestine was 
taken out, the first 5 cm (duodenum) discarded, and the lumen of the next 30 cm 
(jejunum) was flushed with ice cold PBS for 3 times, opened longitudinally and 
blotted dry with a blotting paper. The mucosal layer was scrapped off from the 
epithelial layer with a glass slide on ice and transferred to 10 mL of ice cold 
homogenizing buffer consisted of 0.05 M Tris at pH 7.8 with Complete ® protease 
inhibitor cocktail (Roche), and stored at -80�C until analysis. 
2.3.1.3 Intestinal acyl coenzyme A: cholesterol acyltransferase (ACAT) activity 
measurement 
Intestinal ACAT activity was measured as described previously by Cadigan & 
Chang (1988), Chang et al (1998), Diczfalusy et al (1996)，Heider et al (1983), and 
Zhang et al (2003). 
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2.3.1.3.1 Preparation of intestinal microsome 
The mucosa sample was thawed and then homogenized in a homogenizer 
(Wheaton, San Diego, CA, U. S. A.) for 10 strokes on ice. The mixture was then 
centrifuged at 800 x g for 15 minutes at 4�C. The supernatant containing the cytosol 
was transferred to a new vial and the pellet containing cell debris was discarded. The 
ssupematant was then centrifuged again was repeated at 800 x g for 15 minutes at 4°C. 
The resultant supernatant was then transferred to a polycarbonate centrifuge tube 
(Beckman) and centrifuged at 100,000 x g for 60 minutes at 4 The supernatant 
was then discarded and the microsome pellet was resuspended in 1 niL homogenizing 
buffer (0.05 M Tris, 1 M KCl, with Complete ® protease inhibitor cocktail (Roche)). 
CHAPS (Sigma) was then added to the resuspension with constant mixing to final 
concentration of 2% (w/v). The resuspension was then considered as the microsome 
and stored at -80 until analysis. Aliquot of the microsome was taken for protein 
concentration using a commercial protein assay kit (Bio-rad) according to the 
manufacturer's instructions. 
2.3.1.3.2 ACAT activity assay 
Microsome was adjusted with solubilization buffer to a protein concentration of 
1 mg/ 150 jaL. 400 nmol of cholesterol in 45% (w/v) 2-hydroxypropyl P-cyclodextrin 
aqueous solution was added to 1 mg of microsome and incubated on ice for 30 
minutes and then in a 37 °C water bath for 5 minutes to equalize temperature. The 
reaction was initiated by adding an assay reagent of 0.517 nmol of ['"^C] 
oleoyl-Coenzyme A (0.03i^Ci) (Perkin-Elmer, Waltham, MA, U. S. A.), 7.483 nmol 
of non-radioactive oleoyl-Coenzyme A (Sigma) and 10 nmol of fatty acid-free bovine 
serum albumin (Sigma) and the reaction mixture was incubated in a 37 °C water bath 
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for 20 minutes. The reaction was then stopped by adding 4.8 mL chloroform: 
methanol mixture (2:1，v/v) and ImL saline and then chilling on ice. After the 
addition of 10 |_ig [^H] cholesterol oleate (0.002 )j.Ci) (as internal standard for loss 
corrrection), the mixture was centrifuged at 800 x g for 10 minutes at 4 °C and the 
lower organic layer was collected and transferred to a new tube and evaporated under 
a gentle nitrogen stream until dryness. 10 of cholesteryl oleate in 50 fiL of 
chloroform was then added and the tube was vortexed thoroughly. The resuspension 
was then spotted on a thin-layer chromatography (TLC) plate (Merck, NJ, U. S. A.) 
and then developed in hexane: ethyl acetate: acetic acid (80:20: 1，v/v) for 45 minutes. 
After drying, the plate was stained in iodine vapor. The band corresponding to 
cholesterol oleate was cut off according to a cholesteryl oleate standard developed in 
parallel and transferred to a scintillation vial. 10 mL of OptiPhase HiSafe 2 
scintillation fluid (Perkin-Elmer) was added to the vial which was incubated with 
agitation overnight. Radioactivity was then measured in an LS 6500 scintillation 
counter (Beckman) and the data was calculated based on [^H] recovery. 
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2.3.2 Results 
2.3.2.1 Growth and food intake 
The body weight and food intake of the hamsters are shown in Table 2.7. No 
significant difference in amount of food intake or body weight was observed in the 
hamsters among the control, LA, CLA, LN or CLN groups. 
2.3.2.2 Organ weights 
Weights of liver, adipose tissues (epididymal and perirenal pads), kidneys and 
hearts of the hamsters are shown in Table 2.8. 
Weights of liver of hamsters fed CLA were significantly higher than that of the 
hamsters fed the control diet. Weights of epididymal and perirenal adipose pads of 
hamsters fed CLA and perirenal adipose pad of LN were significantly lower than 
those fed the control diet. Kidneys of hamsters fed CLA weighed significantly higher 
than those fed the control diet. No significant difference in weights was observed in 
other organs. 
2.3.2.3 Effect of ODA on serum TC, TG and HDL-C 
Serum TC of hamsters fed LA, CLA and LN were significantly lower than that 
of the control, but TC of CLN group was not significantly different from that of the 
control. To be specific, TC of LA, CLA and LN were 15.0%, 24.2% and 24.2% lower 
than the control. There was no significant difference in TC among LA, CLA and LN. 
(Table 2.9) Serum HDL cholesterol were not significantly different among the groups. 
Non-HDL cholesterol /HDLcholesterol ratio of CLA and LN, but not LA and CLN 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































No significant difference in serum TG was observed among the hamsters fed the five 
experimental diets. 
2.3.2.4 Effect of ODA feeding on fecal neutral sterol content 
Fecal neutral sterol content of the hamsters fed CLA and LN was significantly 
higher than the control, while that of hamsters fed LA and CLN was not significantly 
different (Figure 2.19). 
2.3.2.5 Effect of ODA feeding on fecal acidic sterol content 
Concentration of fecal acidic sterol output is shown in Figure 2.20. There was no 
significant difference in acidic sterol levels in hamsters with or without ODA feeding. 
2.3.2.6 Effect of ODA feeding on intestinal acyl coenzyme A: acyl cholesterol 
transferase (ACAT) activity 
The intestinal ACAT activity of hamsters fed CLA and LN, but not LA or CLN, 
was significantly lower than that of the control (Figure 2.21). Hamsters fed LA had 
their intestinal ACAT activity reduced by 63.6% compared with the control while 
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Figure 2.19 Effect of octadecaenoic acid (ODA) feeding on fecal neutral sterol 
content. Values are expressed as means 土 S.D. (n=10). Bars with different 
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Figure 2.20 Effect of octadecaenoic acid (ODA) feeding on fecal acidic sterol 
content. Values are expressed as means 土 S.D. (n=10). 
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Figure 2.21 Intestinal acyl coenzyme A: acyl cholesterol transferase (ACAT) 
activity in hamsters fed LA, CLA, LN and CLN. Values are expressed as 
means 土 S.D. (n=10). Bars with different letters (a, b and c) are significantly 
different at p<0.05. 
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2.4 Discussion 
LA, CLA, LN and CLN are four structurally similar PUFAs. Experiments 1 and 
2 clearly demonstrated that they exerted different effects on blood cholesterol in 
hamsters. LA, CLA and LN reduced blood TC while CLN did not. Previous studies 
had shown that both LA and CLA were hypocholesterolemic (de Deckere et al, 1999; 
Navarro et al, 2003; Navarro et al, 2005; Navarro et al, 2006; Wilson et al, 2006; 
Yeung et al, 2000), while LN but not CLN reduced blood cholesterol (Dhar & 
Bhattacharyya, 1998; Dhar et al, 1999; Yeung et al, 2000). The present results is in 
agreement with these previous reports. 
In experiment 1，while reduction in TC was observed in the hamsters fed LA, 
CLA and LN, no change in HDL-C was observed among these groups. Therefore, 
reduction in cholesterol in serum occurred mainly in the non-HDL lipoprotein class. 
In fact, nHDL-C/HDL-C ratio was also significantly lower in CLA and LN groups 
than in the control group. It is known that LDL-C/HDL-C ratio is a strong predictor of 
CHD incidence. Therefore, dietary supplementation of LA, CLA and LN induces 
favorable change in the distribution of lipoproteins. 
Blood TG responded to ODA supplementation in an inconsistent manner. In this 
study, no significant difference in TG was observed in the ODA-fed and the control 
hamsters. However, Dhar and Bhattacharyya (1999) reported an increase in TG in rats 
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fed CLN while Navarro (2006) observed an decrease in TG in hamsters fed CLN. 
Yeung (2000) had shown that CLA but not LA increased fecal neutral sterol 
output with bile acid output being unaffected. In this study, we confirmed that CLA 
elevated fecal neutral sterol content and also showed that LN but not CLN increased 
fecal neutral sterol output. This suggests that LN and CLA share the property of 
increasing neutral sterol excretion in the feces. Increase in neutral sterol content 
suggests a lower efficiency of cholesterol absorption in the intestine. 
Absorption of cholesterol was the lowest in the CLA-fed hamsters among the 
five groups (Table 2.5). Similarly, cholesterol absorption was significantly reduced in 
hamsters fed LA. In contrast, cholesterol absorption in the LN group seemed to be 
lower than the control, although the difference was not statistically significant. The 
present cholesterol balance study demonstrated clearly that the varying effects of 
ODA on blood cholesterol were associated with their effect on absorption of dietary 
cholesterol. 
Hepatic cholesterol levels in all ODA-treated hamsters were lower than that in 
the control. This was in agreement with previous reports (Navarro et al, 2006; Wilson 
et al, 2006). Interestingly, liver cholesterol level was significantly and positively 
associated with blood TC and nHDL-C/HDL-C ratio (Figures 2.7 and 2.9). High liver 
cholesterol was associated with not only high blood TC, but also non HDL-C. This 
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suggests that the liver plays an important role in the regulation of blood cholesterol 
and also distribution of cholesterol in different lipoprotein classes. 
However, no significant difference was observed in the hepatic protein of 
SREBP-2, HMGR, LDLR, LXR, and CYP7A1 among the five groups. No significant 
difference was observed in the mRNA level of LDLR, LXR and CYP7A1. Current 
knowledge on protein and mRNA abundances of these proteins affected by PUFAs in 
vivo is limited. A previous study reported that CLA did not affect mRNA levels of 
SREBP-la and SREBP-Ic in hamsters fed an atherogenic diet (Zabala et al, 2004). 
Since theses proteins function as the regulation points of input and output of 
cholesterol in the liver, it is suggested that homeostatic regulation of cholesterol 
induced by ODAs did not occur at transcriptional or translational levels in vivo under 
the current experimental conditions. No significant difference was observed in plasma 
CETP activity and hepatic CETP mRNA among all groups. CETP regulates the 
distribution of cholesterol between HDL and LDL. There was no evidence that the 
reduction in non HDL-C in LA, CLA and LN groups were brought about by 
alternation in CETP activity. 
In view of association between increased fecal cholesterol output and lower 
blood cholesterol, experiment 2 was conducted to further investigate whether 
reduction in cholesterol absorption was due to intestinal ACAT inhibition. The blood 
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lipid profile of the hamsters in experiment 2 showed the same trend as that in 
experiment 1. The results are in agreement with previous reports (de Deckere et al, 
1999; Dhar & Bhattacharyya，1998; Dhar et al, 1999; Navarro et al, 2003; Navarro et 
al, 2005; Navarro et al, 2006; Wilson et al’ 2006; Yeung et al, 2000). TC in hamsters 
fed LA, CLA and LN diets but not CLN diet were significantly lower than the control. 
HDL-cholesterol was not affected by ODA supplementation while 
non-HDL-cholesterol was significantly lowered in hamsters fed LA, CLA and LN diet. 
Interestingly, significant decreases in blood TG levels were also observed in LA, CLA 
and LN fed hamsters, while a similar trend but no significant difference were 
observed in the hamsters in experiment 1. As for fecal neutral sterol, significantly 
higher output was observed in CLA and LN fed hamsters but not in those fed LA and 
CLN. In general, the results in experiment 1 were reproduced in experiment 2. 
It was clearly demonstrated in experiment 2 that decrease in blood cholesterol in 
CLA and LN fed hamsters was associated with an increase in fecal neutral sterol 
excretion, and also a decrease in intestinal ACAT activity. This was in agreement with 
the previous report of our laboratory that CLA but not LA reduced intestinal ACAT 
activity in hamsters (Yeung et al, 2000). Esterification of cholesterol by ACAT is an 
essential and rate-limiting step in intestinal cholesterol absorption, and intestinal 
ACAT activity is thus associated with intestinal cholesterol absorption efficiency 
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(Haugen & Nomm, 1976; Parini et al, 2004; Repa et al, 2004; Willner et al, 2003). 
Reduced ACAT activity and increased fecal neutral sterol excretion suggest a reduced 
intestinal neutral sterol absorption in CLA and LN fed hamsters. Reduced cholesterol 
absorption essentially reduces incorporation and influx of cholesterol into the body, 
thus counteracting the effect of cholesterol load from the experimental diet on blood 
cholesterol. Previous reports had also shown that ACAT inhibition by pharmaceutic 
agents led to a 60% decrease in blood cholesterol in rats (Roth et al, 1992). 
In summary, we found that LA, CLA, LN and CLN had no effect on SREBP-2, 
HMGR, LDLR, LXR and CYP7A1 at both transcriptional and translational levels in 
hamsters. Neither association was found between plasma CETP activity and blood 
cholesterol distribution neither. However, the present studies clearly demonstrated 
hamsters fed LA, CLA and LN but not CLN diet had lower intestinal ACAT activities, 
which led to lower intestinal cholesterol absorption efficiencies. This can explain, at 
least in part, the underlying mechanism of why LA, CLA, LN but not CLN lowered 
blood TC and non-HDL cholesterol levels. 
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Chapter 3 
Effect of Octadecaenoic Acids on 
Cholesterol-regulating Genes in HepG2 
3.1 Introduction 
3.1.1 HepG2 as a model of cholesterol regulation 
The liver plays an important role in cholesterol metabolism in vivo. As described 
in Chapter 1，over 50% of cholesterol synthesis occurs in the liver, which also 
regulates the excretion of cholesterol from the body. The liver is therefore considered 
as the single most important organ in cholesterol metabolism (Dietschy et al, 1993; 
Kruit et al, 2006; Repa & Mangelsdorf，2000; Yao et al, 2007). Cell lines from 
hepatocyte origins are therefore ideal models for the study of cholesterol metabolism 
in vitro. 
HepG2 is a cell line derived from the hepatic carcinoma of a 15-year-old male 
Caucasian. It is a perpetual adherent and morphologically epithelial cell line. Its 
nature as a cancer cell line allows rapid proliferation and it has been a popular cell 
line chosen for the study of cholesterol homeostasis (Bejta et al, 2007; Morikawa et al, 
2007; Qian et al, 2007; Shin et al, 2007). HepG2 has been shown to possess many 
liver-specific functions (Havekes et al, 1987). It has also been shown that many genes 
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involved in cholesterol synthesis and degradation are retained in HepG2, including 
SREBP-2 (Mullen et al, 2004), HMGR (Busch et al, 1990)，apoA (Cuthbert et al, 
1997)，LDLR (Lovati et al, 2000; Yu-Poth et al, 2004)and CYP7A1 (Morikawa et al, 
2007; Pandak et al, 1996). We have therefore chosen HepG2 as the cell culture model 
for the study of the effect of ODA on cholesterol metabolism. 
3.1.2 Effect of polyunsaturated fatty acids (PUFAs) on cholesterol regulating 
genes in cultured cells 
It remains unclear how individual fatty acids affect the mRNA and protein levels 
of genes involved in cholesterol metabolism. Some animal studies found that 
saturated fatty acids reduced LDLR activity, protein and mRNA levels while PUFAs 
had an opposite effect (Kurushima et al, 1995; Mustad et al, 1996; Woollett et al, 
1992). However, some other studies found no effects on these genes brought about by 
the fatty acids (Hennessy et al, 1992; Ringseis et al, 2006a; Sorci-Thomas et al, 1989). 
Inconsistent results are also found in in vitro studies. Some researchers found that 
PUFAs increased LDLR mRNA levels while others found PUFAs increased LDLR 
activity but not mRNA (Lindsey et al, 1992; Srivastava et al, 1995; Yu-Poth et al, 
2005). 
The enzyme activity of HMGR, the rate-limiting enzyme in cholesterol synthesis, 
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was found to decrease in cells treated with long chain PUFAs (Vignikin et al, 1989). 
In another study, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were 
found to down-regulate HMGR activity but not mRNA level in breast cancer cells 
MCF-7 (Duncan et al, 2005). 
As for CYP7A1, inconsistent results were also observed. CYP7A1 mRNA and 
bile acid excretion were found to increase simultaneously in mouse fed fish oil 
(Berard et al, 2004). In another study, mice fed a saturated fatty acid-rich diet had 
their CYP7A1 decreased, along with increased blood and liver cholesterol compared 
with the control (Li et al, 2005). Interestingly, in the same study, mice fed a long 
chain polyunsaturated fatty acid-rich diet still had their CYP7A1 mRNA decreased 
but the bile acid excretion increased while blood and liver cholesterol were found to 
decrease (Li et al, 2005). To the best of our knowledge, there is to date no report on 
the effect of fatty acids on CYP7A1 of a cultured cell model. 
Summing up the above literature review, the previous effects of individual fatty 
acids on the expressions of genes involved in cholesterol metabolism in cultured cells 
are limited and some are even conflicting. There are especially few reports on the 
effect of individual 18-C PUFAs on these cholesterol regulators. It is therefore of 
importance to investigate the effects of some selected ODA, namely, LA, CLA and 
LN on the genes involved in cholesterol regulation in cell culture model. 
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3.1.3 Objectives 
In chapter 2, the mechanism by which LA, CLA and LN reduced blood 
cholesterol was not explained by the hepatic cholesterol-regulating genes in vivo. The 
objectives of the present study were to investigate the effect of ODA on the mRNA 
and protein abundances of these genes in vitro on a HepG2 model. 
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3.2 Materials and Methods 
3.2.1 Cell culture 
The cell culture experiment was performed in a protocol modified from Yu-poth 
et al (2004) and Rumsey et al (1995). HepG2 cell line was purchased from American 
Type Culture Collection (Manassas, VA, U. S. A.). The cells were routinely 
maintained in 75 cm^ culture flask with RPMI-1640 medium (Gibco™, Invitrogen, 
CA, U. S. A.) supplemented with 10% (v/v) fetal bovine serum (Gibco^M, Invitrogen), 
100 U/mL penicillin (Gibco™, Invitrogen) and 100 |ig/mL streptomycin (Gibco™, 
Invitrogen) in a humidified atmosphere containing 5% CO2 and 95% air at 37°C. The 
medium was replenished every three days and the cells were passed to a new flask 
when the cells reached 70-80% confluent. During cell passage, the flask was washed 
with 5 mL of phosphate-buffered saline (PBS) and then incubated with 2 mL of 
EDTA-trypsin (Gibco™, Invitrogen) for 5 minutes in a humidified atmosphere 
containing 5% CO2 and 95% air at 37°C. The detached cells were washed by 10 mL of 
PBS and centrifuged at 1500 rpm for 10 minutes. The pelleted cells were then 
resuspended in 2 mL of prewarmed fresh medium described above. 500 )iL of the cell 
resuspension was transferred into a new 75 cm^ culture flask containing 11.5 mL 
prewarmed medium. 
For cell stock storage, the cell pellet obtained after trypsinzation and 
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centrifugation was resuspended with 3 mL of freezing medium containing 90% 
chilled fresh medium described above and 10% (v/v) dimethyl sulfoxide (DMSO) 
(Sigma). 1 mL of the aliquot was transferred to a cryogenic vial (Coming, NY, 
Canada), which was then put in a cryogenic freezer (Coming) at -80°C overnight and 
then stored under liquid nitrogen. 
To maintain a cell line from the stock, the cryogenic vial was taken from liquid 
nitrogen and allowed to thaw in a 37°C water bath until it just melted. The mixture 
was diluted with 10 mL of fresh medium and centrifuged at 1800 rpm for 5 minutes 
and the process is repeated once. The cells were finally resuspended in 2 mL of fresh 
medium and transferred into a 75 cm^ culture flask containing 10 mL prewarmed 
fresh medium and incubated in a humidified atmosphere composed of 5 % CO2 and 
95% air at SV^^ C. 
To study the effect of ODA-supplementation on HepG2, 1x10^ of cells were 
seeded on a 100 mm^ culture dish on day 0. On day 3，the medium was removed and 
the dish was rinsed with 5 mL PBS for three times, followed by the addition of a 
defined serum free medium consisting of RPMI-1640 (Gibco™, Invitrogen，)，100 
U/mL penicillin (Gibco™, Invitrogen) and 100 jug/niL streptomycin (GibcoTM， 
Invitrogen) and 1.5% (w/v) fatty acid-free BSA (Sigma) for 24 hours. On day 4’ the 
medium was removed and replaced with the control medium or the 
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ODA-supplemented medium for 24 hours. After the incubation, the medium was 
removed and the dish was rinsed with 5 mL PBS for 3 three times and the cells were 
harvested for analysis. 
To prepare the ODA-supplemented media, LA, CLA and LN were purchased 
from Sigma and were dissolved in 100% ethanol into LA, CLA and LN-stock 
solutions. The stock solutions were then slowly added below the surface-air interface 
to prevent dispersion of fatty acid over the surface, and were thoroughly dissolved in 
the defined serum free medium prewarmed to 37°C. The concentrations of 
BSA-bound LA, CLA and LN were adjusted to 0.4 mmol/L and that of ethanol was 
adjusted to 0.05% (v/v) in the experimental media. A concentration of 0.4 mmol/L of 
the BSA-bound fatty acid was determined by Yu-poth et al (2004) as a physiological 
concentration. The control medium was prepared by the addition of fatty acid-free 
BSA to a concentration of 1.5% (w/v) and ethanol to 0.05% (v/v) without the addition 
of ODA. 
3.2.2 Measurement of SREBP-2, LDLR, HMGR and CYP7A1 protein 
abundance by Western blotting 
Cellular protein was extracted in a method modified from Vaziri et al (1996). In 
brief, the cells were scrapped on ice with a cell scrapper in 2 mL of PBS (Coming), 
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followed by centrifugation at 1800 rpm for 5 minutes, and the supernatant above the 
cell pellet was aspirated and 200 |iL of ice-cold homogenizing buffer (20mM 
Tris-HCl (pH 7.5), 2mM MgCh, 0.2 M sucrose and Complete ® protease inhibitor 
cocktail (Roche)) was added. After brief sonication, the samples were centrifuged at 
12, 000 g for 15 minutes at 4 to remove cell debris. The supernatant was then 
saved, considered as the protein extract and stored at -20°C until analysis. 
The remaining procedure for Western blotting was the same as described in 
Section 2.2.1.6, except that 25 i^ g of total protein was used in the detection of HMGR 
and LXR while 40^g was used for SREBP-2 and CYP7A1. 
3.2.3 Measurement of cellular SREBP-2, LDLR, HMGR, LXR, CYP7A1 and 
CETP mRNA by real time PGR 
RNA in the cells was extracted with Trizol reagent (Invitrogen) according to the 
manufacturer's instructions. In brief, 1 mL of Trizol was added into the culture dish 
and the cells were lyzed. The remaining procedures of RNA extraction, cDNA 
synthesis and real time PGR analysis were the same as described in chapter 2. 
3.2.4 Statistics 
Results were presented as means 士 standard deviation (S.D.). Where applicable, 
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statistical significance of differences between groups was assessed by one-way 
analysis of variance (ANOVA) followed by Student's /-test, or Pearson's correlation 
coefficient, using Prism® (Graphpad software, Inc., CA, U. S. A.). Differences 
between groups were considered significant when P<0.05. 
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3.3 Results 
3.3.1 Effect of ODA on HepG2 SREBP-2 immunoreactive mass 
HepG2 SREBP-2 immunoreactive mass as revealed by Western blot analysis is 
shown in Figure 3.1. There was no significant difference in SREBP-2 immunoreactive 
mass between cells supplied with control and ODA supplemented media. 
3.3.2 Effect of ODA on HepG2 HMGR immunoreactive mass 
HepG2 HMGR immunoreactive mass as revealed by Western blot analysis is 
shown in Figure 3.2. There was no significant difference in HMGR immunoreactive 
mass between cells supplied with control and ODA supplemented media. 
3.3.3 Effect of ODA on HepG2 LDLR immunoreactive mass 
HepG2 LDLR immunoreactive mass as revealed by Western blot analysis is 
shown in Figure 3.3. There was no significant difference in LDLR immunoreactive 
mass between cells supplied with control and ODA supplemented media. 
3.3.4 Effect of ODA on HepG2 LXR immunoreactive mass 
HepG2 LXR immunoreactive mass as revealed by Western blot analysis is 
shown in Figure 3.4. CLA and LN supplementation significantly increased LXR 
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immunoreactive mass while there was no significant difference in LXR 
immunoreactive mass between control and LA-supplemented cells. More specifically, 
CLA and LN increased LXR immunoreactive mass by 12 and 9 % respectively. 
3.3.5 Effect of ODA on HepG2 CYP7A1 immunoreactive mass 
HepG2 CYP7A1 immunoreactive mass as revealed by Western blot analysis is 
shown in Figure 3.5. There was no significant difference in CYP7A1 immunoreactive 
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Figure 3.1 Relative abundance of HepG2 SREBP-2 immunoreactive mass as 
determined by Western blot analysis. Data are normalized with p-tubulin so 
that value of the control group is regarded as 1.0. Values are expressed as 
means 土 S. D. (n=5). 
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Figure 3.2 Relative abundance of HepG2 HMGR immunoreactive mass as 
determined by Western blot analysis. Data are normalized with p-tubulin so 
that value of the control group is regarded as 1.0. Values are expressed as 
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Figure 3.3 Relative abundance of HepG2 LDLR immunoreactive mass as 
determined by Western blot analysis. Data are normalized with (3-tubulin so 
that value of the control group is regarded as 1.0. Values are expressed as 
means 土 S. D. (n=3). 
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Figure 3.4 Relative abundance of HepG2 LXR immunoreactive mass as 
determined by Western blot analysis. Data are normalized with (3-tubulin so 
that value of the control group is regarded as 1.0. Values are expressed as 
means 土 S. D. (n=5). 
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Figure 3.5 Relative abundance of HepG2 CYP7A1 immunoreactive mass as 
determined by Western blot analysis. Data are normalized with (3-tubulin so 
that value of the control group is regarded as 1.0. Values are expressed as 
means 土 S. D. (n=5). 
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3.3.6 Effect of ODA supplementation on HepG2 SREBP-2 mRNA expression 
HepG2 SREBP-2 mRNA abundance as revealed by real time PGR is shown in 
Figure 3.6. CLA supplementation significantly increased SREBP-2 gene expression 
while there was no significant difference in SREBP-2 gene expression among the 
control, LA and LN-supplemented cells. More specifically, CLA increased SREBP-2 
mRNA by 5.6 fold. 
3.3.7 Effect of ODA supplementation on HepG2 HMGR mRNA expression 
HepG2 HMGR mRNA abundance as revealed by real time PGR is shown in 
Figure 3.7. Supplementation of ODA did not significantly change HMGR gene 
expression level. Although the mean HMGR mRNA expression level of CLA 
supplemented cells is higher than the control, the difference was not statistically 
significant. 
3.3.8 Effect of ODA supplementation on HepG2 LDLR mRNA expression 
HepG2 LDLR mRNA abundance as revealed by real time PGR is shown in 
Figure 3.8. CLA supplementation significantly increased LDLR gene expression 
while there was no significant difference in LDLR gene expression among the control, 
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Figure 3.6 Relative SREBP-2 mRNA abundance in HepG2 as determined by 
real time PGR. Data are normalized with (3-actin so that value of the control 
group is regarded as 1.0. Values are expressed as means 土 S. D. (n=5). 
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Figure 3.7 Relative HMGR mRNA abundance in HepG2 as determined by real 
time PCR. Data are normalized with (3-actin so that value of the control group 
is regarded as 1.0. Values are expressed as means 土 S. D_ (n=5). 





g 12.0 •w 0) <D 
J 10.0 
LU 0) c 
a> 8 0 -O • • I • 
0.0 1 — b S B — I — H — I — — I 
Control LA CLA LN 
Treatment 
Figure 3.8 Relative LDLR mRNA abundance in HepG2 as determined by real 
time PGR. Data are normalized with (3-actin so that value of the control group 
is regarded as 1.0. Values are expressed as means 土 S. D. (n=5). 
Means with different superscripts (a, b) differ significantly at p<0.05. 
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3.3.9 Effect of ODA supplementation on HepG2 LXR mRNA expression 
HepG2 LXR mRNA abundance as revealed by real time PGR is shown in Figure 
3.9. CLA supplementation significantly increased LXR gene expression while there 
was no significant difference in LXR gene expression among the control, LA and 
LN-supplemented cells. More specifically, CLA increased LXR mRNA by 5.5 fold. 
3.3.10 Effect of ODA supplementation on HepG2 CYP7A1 mRNA expression 
HepG2 CYP7A1 mRNA abundance as revealed by real time PCR is shown in 
Figure 3.10. CLA supplementation significantly increased CYP7A1 gene expression 
while there was no significant difference in CYP7A1 gene expression among the 
control, LA and LN-supplemented cells. More specifically, CLA increased CYP7A1 
mRNA by 3.8 fold. 
3.3.11 Effect of ODA supplementation on HepG2 CETP mRNA expression 
HepG2 CETP mRNA abundance as revealed by real time PCR is shown in 
Figure 3.11. Supplementation of ODA did not significantly change CETP gene 
expression level. Although the mean CETP mRNA expression level of CLA 
supplemented cells is higher than the control, the difference was not statistically 
significant. 
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Figure 3.9 
Relative LXR mRNA abundance in HepG2 as determined by real time PCR. 
Data are normalized with p-actin so that value of the control group is regarded 
as 1.0. Values are expressed as means 土 S. D. (n=5). 
Means with different superscripts (a, b) differ significantly at p<0.05. 
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Figure 3.10 
Relative CYP7A1 mRNA abundance in HepG2 as determined by real time 
PCR. Data are normalized with (3-actin so that value of the control group is 
regarded as 1.0. Values are expressed as means 土 S. D. (n=5). 
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Figure 3.11 
Relative CETP mRNA abundance in HepG2 as determined by real time PGR. 
Data are normalized with (3-actin so that value of the control group is regarded 
as 1.0. Values are expressed as means 土 S. D. (n=5). 
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3.4 Discussion 
The present study investigated the effect of LA, CLA or LN in HepG2 cells 
affected the mRNA expression and protein abundance of several genes involved in 
cholesterol metabolism. HepG2 was chosen as the cell culture model primarily 
because of its origin from the liver, the most important organ for cholesterol 
homeostasis and metabolism (Havekes et al, 1987). It has also been established that 
HepG2 retains many liver-specific properties and that it mimics normal hepatocytes 
well. 
Chapter 2 showed that supplementation of LA, CLA and LN but not CLN 
reduces blood cholesterol of hamsters. However, no significant differences were 
found in the abundance of protein or mRNA of SREBP-2, HMGR, LDLR, LXR, 
CYP7A1 and CETP in their liver. This study was to investigate whether LA, CLA and 
LN supplementation affect the protein or mRNA levels of these genes using a cell 
culture model. 
The present data suggest that CLA affected the expression of these cholesterol 
regulating genes distinctly from LA and LN. SREBP-2 mRNA was found to be 
increased by CLA but not LA or LN. This is in agreement with a previous report that 
CLA but not LA increased SREBP-2 mRNA in HepG2 (Ringseis et al 2006b). 
However, none of the ODA significantly changed the protein level of SREBP-2. 
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CLA not LA and LN increased LDLR gene expression but none of them altered 
LDLR protein abundance. This confirms the report of Yu-Poth et al (2004; 2005), 
who found that CLA but not LA nor LN increased LDLR transcription. Yu-poth et al 
(2004, 2005) also reported no significant difference in the protein of LDLR by LA, 
CLA and LN. 
HMGR mRNA was also increased by CLA but not LA nor LN. This is again in 
agreement with a report by Ringseis et al (2006b), who found up-regulation of 
HMGR mRNA by CLA but not LA. Since SREBP-2 is the transcription factor for 
HMGR and LDLR (Eberle et al, 2004) (see Section 1.2.2.2)，it is logical that 
up-regulation of SREBP-2, HMGR and LDLR occur simultaneously. This also 
suggests that CLA-induced up-regulation of LDLR and HMGR expression is 
mediated through SREBP-2 transcriptional enhancement. 
CLA was shown to increase both LXR protein and mRNA in the present study. 
In contrast, LN increased LXR mRNA but not its protein, while LA had no effect on 
both LXR protein and its mRNA. Published literature on the effect of ODA on LXR 
in HepG2 is limited and offers no comparable data to the present study. However, the 
simultaneous induction of both protein and mRNA of LXR by CLA provided strong 
validation. 
CYP7A1 induction was observed in cells treated with CLA but LA or LN. There 
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is also no published report that allows direct comparison with the present data. 
However, since LXR is known to be the transcription factor of CYP7A1 (see Section 
1.2.2.5), it is reasonable that up-regulation of CYP7A1 occurs simultaneously with 
LXR. 
We also observed a trend for increased CETP mRNA by in CLA-treated cells, 
although the difference was not statistically significant. LA and LN treated cells 
demonstrated no difference in CETP mRNA level. There is no published data on the 
effect of CLA on CETP expression, and it should be noted that CETP is a protein 
which is functional in the blood and hence it carries no biochemical significance in a 
cell culture system. 
The present study observed a significant increase in mRNA level of SREBP-2, 
LDLR, HMGR and CYP7A1 but not their protein level. Although theoretically, 
translation into protein occurs after transcription of mRNA and mRNA abundance 
regulates protein synthesis, it must be noted that two methods of different principles 
were used in the measurement of protein and mRNA abundances respectively. Protein 
and mRNA levels were respectively assayed with Western blotting and real-time PGR. 
There is to date no report that has proven the two methods are of comparable 
sensitivity. If real-time PGR is more capable of detecting minor differences in mRNA 
level than Western blotting do in protein level, then significant difference in mRNA 
112 
but not in protein might be detected. In fact, since the two methods measures two 
totally different classes of substances, it would be difficult to compare the sensitivity 
between the two methods directly. In fact, difference in mRNA but not protein level in 
LDLR of HepG2 treated with CLA in the absence of oxysterol was also observed in 
other researchers (Yu-Poth et al, 2004). 
The above data clearly demonstrated that CLA had a distinctive effect on the 
cholesterol regulating genes in vitro from LA and LN. While LA and CLA have the 
same number of double bond, the conjugated double bond system in CLA clearly has 
a different effect on SREBP-2, LDLR, HMGR, LXR and CYP7A1, and hence on 
cholesterol metabolism compared with the non-conjugated LA and LN. The present 
data echoes with the previous report of our laboratory that CLA but not LA suppresses 
intestinal ACAT activity (Yeung et al, 2000), showing the distinctive properties of 
CLA. Recently, there had been reports on the isomer-specific effects of c9, t i l CLA 
and clO, t l2 CLA on some genes (Rasooly et al, 2007) and on lipid metabolism in 
hamsters (Bissonauth et al, 2006). The CLA sample (Sigma) we used in this study 
was a 1:1 mixture of the two. Therefore, it will be interesting to investigate the effect 
of these two isomers individually on these genes studied. 
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Chapter 4 
Effect of apple polyphenols on blood cholesterol 
in hamsters 
4.1 Introduction 
4.1.1 Apple is a commonly consumed fruit worldwide 
Apple is the fruit of the Malus genus belonging to the rose family Rosaceae. The 
type of apple most commonly consumed nowadays is Malus domestics among over 
7500 known individual species. Originated in Europe and mid-Asia, it is now 
cultivated extensively around the world. In 2005, total apple production in Asia and 
Europe reached 10466 and 15675 kilotonnes respectively (FAO, 2006). 
In China, both production and consumption of apples have also increased 
substantially over the last decade. Annual production of apples increased from 14017 
kilotonnes in 1995 to 24017 kilotonnes in 2005, while its annual comsumption had 
increased from 12602 kilotonnes in 1995 to 19237 kilotonnes in 2005 (FAO, 2006). 
Apple is becoming a more and more popular fruit in the country. 
4.1.2 Potential health effects of apples 
Traditionally, apples have been regarded as a healthy food in many cultures, as 
seen from the popular proverb ‘one apple a day keeps the doctor away'. In recent 
years, association between apple consumption and several health benefits has been 
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established. Epidemiological studies showed an inverse relationship between apple 
intake and lung cancer (Feskanich et al, 2000; Le Marchand et al, 2000), tumors of 
the alimentary canal (Hertog et al, 1994), breast and ovary cancers (Gallus et al, 
2005), cardiovascular diseases (Sesso et al, 2003), diabetes (Song et al, 2005) and 
hypercholesterolemia (Mee & Gee, 1997). 
Animal experiments investigating the hypocholesterolemic property of apples in 
rats was reported as early as in 1968 (Karvinen & Miettinen，1968). Most of the 
reported studies investigated either whole lyophilized apples (Aprikian et al, 2002; 
Karvinen & Miettinen, 1968), apple pectin (Aprikian et al, 2003; Gonzalez et al, 1998) 
or apple fiber (Mee & Gee, 1997) on cholesterol level. However, there is to date no 
investigation on the specific effect of apple polyphenols (AP) on blood cholesterol. 
4.1.3 Abundance of polyphenols in apple 
Apples are rich in phytochemicals, including carotenoids, flavonoids, 
isoflavonoids and phenolic acids (Boyer & Liu, 2004). The major phenolic 
compounds in apples are quercetin glycosides, vitamin C, procyanidin, chlorogenic 
acid, epicatechin and phloretin glycosides (Lee et al, 2003). Many of such 
phytochemicals are strong antioxidants, and their structures are shown in Figure 4.1. 
Polyphenols exist in both the flesh and the peel of apples. However, the peel has 
higher antioxidant activity than the flesh. Apple peel contained two to six times more 
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phenolic compounds and two to three times more flavonoids than the fresh (Wolfe et 
al, 2003). 
4.1.4 Fuji variety of apple 
Red Fuji variety of apple was chosen as the raw material for investigation of AP 
for two reasons: (i) Red Fuji apple is a major apple species produced in China. It 
accounted for over 64% of total apple harvest in 2005 (Ministry of Agriculture, 2006); 
and (ii) Fuji apple has been shown to have the highest phenolics content compared 
with other varieties (Boyer & Liu, 2004). 
4.1.5 Objectives 
Previous reports on apple's hypocholesterolemic activity investigated either 
whole apple or apple fiber. The objectives of this study were to investigate the effect 




y U x ^ “ o 1 
� O OH H / 
quercetin catechin gaiiic acid 
o 
广 ^ 丨 � H 人 r 义 广 k 人 ⑶ 
phloretin chlorogenic acid 
Figure 4.1 
Structures of antioxidative phenolic compounds in apples. (Modified from 
Boyer & Liu, 2004) 
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4.2 Materials and Methods 
4.2.1 Isolation of AP 
AP extract used in this study was isolated from the waste pomace of Red Fuji 
apple after juice processing. In brief, the pomace was soaked in 70% ethanol in a ratio 
of 1:4 (kg pomace/ liter ethanol) for 1.5 hours twice. The ethanol phases were pooled 
and filtered, and was then concentrated. After de-fatting with n-hexane, the extract 
was purified through adsorption on an AB-8 macroporous resin column. The 
ethanol-eluted phase containing AP was then freeze-dried to obtain AP, which was 
then sprayed dried into reddish-brown powder, stored and sealed at 4°C. 
4.2.2 Characterization of AP extract 
Polyphenol content in the AP was determined by HPLC. In brief, AP sample was 
injected into an HPLC column (Luna Cig lOOA, 250x4.6mm ID) using a Shimadzu 
LC-1 OAT HPLC system equipped with a UV detector. The elution profile was 
programmed at a flow rate of 1 mL/ min, while the gradient mobile phase composed 
of 2% acetic acid (solvent A) and 0.4% acetic acid with 80% acetonitrile (solvent B). 
The ratio of A to B was programmed from 10:1 to 2:8 in 80 minutes and then back to 
10:1 in 3 minutes, and then was held for another 22 minutes. 
4.2.3 Effect of AP on CETP activity in vitro 
Effect of apple polyphenol extract on in vitro CETP enzyme activity was studied 
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using a commercial kit (Amersham Pharmacia Bioscience, Poscataway, NJ, U. S. A.) 
according to the manufacturer's instructions. Briefly, tritium-labeled HDL and 
biotinylated LDL were prepared from human plasma. 10|il of ^H-HDL, biotinylated 
LDL and assay buffer were mixed with 10|LI1 of AP aqueous solutions of various 
concentrations. The reaction was started by mixing lOjil of a partially purified human 
CETP and the mixture was incubated at 3TC for 16 hours. After that, a stop solution 
containing SPA-beads that specifically binded to biotinylated LDL was added to 
detect ^H radiation emitted from LDL. The reaction mixture was read on a Beckman 
LS6500 scintillation counter. 
This measurement was performed in two trials. In the first one, AP 
concentrations tested were 0’ 0.001, 0.01’ 0.1，1 and 10 mg/ mL. In the second trial, to 
further study the dose-response pattern, AP concentrations used were 0，0.01，0.02， 
0.04，0.06’ 0.08，0.1 and 0.5 mg/ niL. 
4.2.4 Effect of AP on blood cholesterol in hamsters 
4.2.4.1 Animals 
Thirty-nine (113±6g) male adult Golden Syrian hamsters {Mesocricetus aumtus) 
were obtained from the Laboratory Animal Services Centre, The Chinese University 
of Hong Kong. They were randomly divided into three groups (n=13) and housed (2 
or 3 per cage) in wire-bottomed cages at 23�C in a 12-hour light-dark cycle animal 
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room. 
Before the experiment, all the animals were allowed to stabilize by being fed a 
high fat high cholesterol diet (control diet). From week 0 to week 6, one group were 
continued to fed the control diet and the other two group were fed a similar diet 
except that they were respectively supplemented with 0.3% (0.3AP) and 0.6% (0.6AP) 
AP polyphenol extract. During the study, food was given daily and any uneaten food 
was discarded. The amount of food consumed was measured each day. The animals 
were free to access to food and distilled water and were weighed weekly. 
Blood (1 mL) was bled from the retro-orbital sinus from the animals into a 
heparinized capillary tube at the end of weeks 0, 3 and 6 after food deprivation for 16 
hours. The blood was centrifuged at 3000rpm for 10 minutes and the plasma was 
collected and stored at -20 °C until analysis. 
The last blood sample was collected on the end of week 6. After a 3-day recovery, 
all hamsters were sacrificed by nitrogen suffocation without fasting. Blood was 
collected from abdominal artery into a vacuum heparinized tube, centrifuged at 800 x 
g at 10 minutes and the plasma was collected and stored at -20°C until analysis. The 
liver, heart, kidney, adipose tissue (perirenal and epididymal pads) were removed, 




The control diet was prepared by mixing the following ingredients in proportion 
(g/kg diet): cornstarch, 508; casein, 242; lard, 50; sucrose, 119; mineral mix AIN-76, 
40; viamin mix AIN-76A, 20; DL-methionine, 1; cholesterol, 1. The two experimental 
diets were prepared by adding 0.3% and 0.6% (w/w) extracts into the control diet 
respectively. The powered diets were mixed with a gelatin solution (20g/L) in a ratio 
of 200g diet per liter of solition. (Table 4.1) Once the gelatin has set, the diets were 
cut into pieces of approximately 10 g cubes and stored forzen at -20°C. 
4.2.4.3 Plasma lipids measurement 
Plasma cholesterol and triglyceride were measured by commercial enzymatic 
kits from Thermo and Stanbio respectively according to the manufacturer's 
instructions. For measurement of plasma HDL-cholesterol, LDL and VLDL were first 
precipitated with phosphotungstic acid and magnesium chloride in a commerical kit 




Composition of the control and two apple polyphenol (AP) diets (g) 
Control 0.3 AP 0.6 AP 
Cornstarch 508 508 508 
Casein 242 242 242 
Lard 50 50 50 
Sucrose 119 119 119 
Mineral mixAIN-76 40 40 40 
Vitamin mix AIN-76A 20 20 20 
DL-methionine 1 1 1 
Cholesterol 1 1 1 
Apple polyphenol extract 0 3 6 
Gelatin 20 20 20 
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4.2.4.4 Plasma CETP activity measurement and immunoreactive mass by 
Western blotting 
The plasma CETP acitivity of the hamsters were measured as previously 
described in section 2.2.1.5, Chapter 2. For measurement of CETP immunoreactive 
mass, plasma was diluted in a buffer containing 20 mM Tris-HCl (pH 7.5)，2mM 
MgCb, 0.2 M sucrose and protease inhinitor cocktail pellet (Complete®，Roche 
Mannheim, Germany). The diluted sample (0.01|j.L) was size-separated on 7% 
SDS-PAGE at 120V for 2 hours. After electrophoresis, the proteins were transferrred 
on a Hybond-P PVDF membrane (Amersham Pharmacia Biosciences) with a 
semi-dry transfer cell (Bio-rad) at 15 V for 1 hour. The membrane was blocked in a 
blocking solution (IX Tris-buffered saline, 0.1% Tween-20 and 5% non-fat milk) at 
4°C for 1 hour and then overnight at 4°C in the same solution containing 1:600 
anti-CETP antibody (Abeam pic, Cambridge, UK). The membrane was then washed 
three times for 10 minutes and then incubated in the blocking solution containing 
1:3000 horseradish peroxidase-linked anti-rabbit IgG (Abeam pic, Cambridge, UK) at 
4°C for 1 hour. The washes were repeated before the membranes were developed with 
ECL chemiluminescent agent (Amersham Life Science) and subjected to 
autoradiography for one to five minutes on SuperRX medical X-ray film (Fuji). Band 
size and optical density were quantified using the computer software Photoshop® 
(Adobe Systems Inc, CA，USA). 
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4.2.4.5 Measurement of liver SREBP-2, LDL-R, HMG-R and CYP7A1 protein 
abundance by Western blotting 
Hepatic protein extraction and Western blotting analysis of liver SREBP-2, LDLR, 
HMGR and CYP7A1 were carried out as previously described in section 2.2.1.6, 
Chapter 2. 
4.2.4.6 Statistics 
Results were presented as means士 standard deviation (S.D.). Where applicable, 
statistical significance of differences between groups was assessed by one-way 
analysis of variance (ANOVA) followed by Student's /-test，using Prism® (Graphpad 




4.3.1 Polyphenol content in AP 
A typical HPLC diagram is shown on Fig. 4.2. The peaks identified included 
chlorogenic acid, phloridzin, catechin and epicatechin. 
4.3.2 Effect of AP on CETP activity in vitro 
Transfer of ^H-cholesterol from HDL to LDL decreased as AP concentration 
increased. In the first trial, CETP activity dropped significantly at AP concentration 
higher than 0.01 mg/ mL (Figure 4.3A). In the second trial, significant decrease in 
^H-cholesterol transfer occurred at AP concentrations higher than 0.02 mg/ mL 
(Figure 4.3B). 
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Figure 4.2 
HPLC chromatogram of apple polyphenols (AP) prepared from Red Fuji 
Apples. For AP extraction process, see 4.2.1. For HPLC profile conditions, see 
4.2.2. Identification of peaks: 3=catechin; 4=chlorogenic acid; 6=epicatechin; 
11=phloridzin. Peaks 1, 2, 5，7，8, 9，10=unknown. 
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Figure 4.3 
Concentration-response curves of AP on in vitro CETP activity. (A) The first 
trial: CETP activity decreased at AP concentrations higher than 0.01 mg/mL. 
(B) The second trial: effect of AP concentration ranged 0-0.5 mg/mL on CETP 
activity. Data are normalized so that CETP activity of the control group is 
regarded as 100%. Values are expressed as means 士 SD (n=3). Values with 
different letters (a, b, c, d, e, f) are significantly different from that of their 
control at p<0.05. 
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4.3.3 Growth and food intake 
The gain of body weight and food intake are shown in Table 4.2. No significant 
differences in body weight and food intake were observed among the control, 0.3AP 
and 0.6AP groups. 
4.3.4 Organ weights 
The weights of liver, kidneys and heart are shown in Table 4.3. The liver weights 
of of 0.3 AP and 0.6 AP groups were not significantly different from the control. 
There was no significant difference in kidney weights among the three groups. 
However, the heart weights of the 0.6 AP group was significantly lower than that of 
the control group by 13%. 
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Table 4.1 
Body weight gain and food intake of the hamsters 
Control 0.3 AP 0.6 AP 
Initial body weight (g) 113.5±5.5 115.8±4.5 111.2±7.2 
Final body weight (g) 120.8±10.0 120.8±7.7 114.2±7.9 
Food intake (g/day) 10.3±1.4 10.2±1.4 9.7±1.4 










































































































































































































4.3.5 Effect of AP supplementation on the plasma lipid profile of hamsters 
Plasma TC in hamsters fed AP diets was not significantly different from that of 
the control. However, plasma HDL-C of the AP-fed hamsters was found to be 
significantly higher than that of the control (Table 4. 4). To be specific, HDL-C of 0.3 
AP and 0.6 AP groups was 14.7% and 16.5% higher than that of the control, 
respectively. In contrast, nHDL-C in the 0.3 AP and 0.6 AP groups were significantly 
lower than the control by 20.0% and 36.7% respectively, leading to a lower ratio of 
nHDL-C to HDL-C in the AP fed groups than in the control (Table 4. 4). 
Plasma TG in the 0.3 AP group was not significantly different from the control 
but that of the 0.6 AP group was significantly lower than the control by 31.9% (Table 
4. 4). 
4.3.6 Effect of AP feeding on plasma CETP activity of the hamsters 
Plasma CETP activity in hamsters fed the AP diets was significantly lower than 
that of the control. To be specific, plasma CETP activity of the 0.3 AP and 0.6 AP 
groups was 71.7% and 70.1% of the control (Figure 4.4). 
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Table 4. 4 
Effect of AP feeding on plasma triglycerides (TG), total cholesterol (TC), 
high-density lipoprotein cholesterol (HDL-C), non-HDL cholesterol (nHDL-C) 
and the ratio of nHDL-C to HDL-C in the hamsters. 
Control 0.3 AP 0.6 AP 
TC (mg/ dL) 199 土 28 197 ±26 184 ± 12 
HDL-C (mg/dL) 109 ± 18匕 125±15a 127±13a 
LDL-C (mg/ dL) 90 ± 13a 72 ± 15b 57 士 11。 
nHDL-C/ HDL-C (mg/ dL) 0.84 土 0 . 1 2 a o . 5 8 ±0.10'' 0.46 土 0 . 1 i c 
Triglycerides (mg/ dL) 144 ±31 ' 142 ±45 ' 98 ± 28b 
Values are expressed as mean 士 S. D. (n=13). nHDL-C was calculated by 
subtracting HDL-C from TC. 
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Figure 4.4 
Plasma CETP activity in the hamsters fed the control and AP-supplemented 
diets. Hamsters fed both 0.3% and 0.6% AP diets had significantly reduced 
plasma CETP activity than the control. Data are normalized so that CETP 
activity of the control group is regarded as 100%. Values are expressed as 
means 土 S.D. (n=13). Means with different superscripts (a, b) differ 
significantly at p<0.05. 
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4.3.7 Effect of AP on plasma CETP immunoreactive mass 
Plasma CETP Immunoreactive mass as revealed by Western Blot analysis is 
shown in Figure 4. 5. There was no significant difference in CETP immunoreative 
mass between the control and AP supplemented hamsters. 
4.3.8 Effect of AP on liver SREBP-2 immunoreactive mass 
Liver SREBP-2 immunoreactive mass as revealed by Western Blot analysis is 
shown in Figure 4. 6. There was no significant difference in SREBP-2 
immunoreactive mass between the control and the AP supplemented hamsters. 
4.3.9 Effect of AP on liver LDLR immunoreactive mass 
Liver LDLR immunoreactive mass as revealed by Western Blot analysis is 
shown in Figure 4. 7. There was no significant difference in LDLR immunoreactive 
mass between the control and the AP supplemented hamsters. 
4.3.10 Effect of AP on liver HMGR immunoreactive mass 
Liver HMGR immunoreactive mass as revealed by Western Blot analysis is 
shown in Figure 4. 8. There was no significant difference in HMGR immunoreactive 
mass between the control and the AP supplemented hamsters. 
4.3.11 Effect of AP on liver CYP7A1 immunoreactive mass 
Liver CYP7A1 immunoreactive mass as revealed by Western Blot analysis is 
shown in Figure 4. 9. There was no significant difference in CYP7A1 immunoreactive 
mass between the control and the AP supplemented hamsters. 
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Figure 4.5 
CETP immunoreactive mass measured by Western Blotting. Data are 
normalized so that value of the control group is regarded as 1.0. Values are 
expressed as means 土 S.D. (n=13). 
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Figure 4. 6 
Relative abundance of hepatic SREBP-2 immunoreactive mass as determined 
by Western Blot analysis. Data are normalized with p-tubulin so that value of 
the control group is regarded as 1.0. Values are expressed as means 土 S.D. 
(n=13). 
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Figure 4. 7. 
Relative abundance of hepatic LDLR immunoreactive mass as determined by 
Western Blot analysis. Data are normalized with |3-tubulin so that value of the 
control group is regarded as 1.0. Values are expressed as means 土 S.D. 
(n=13). 
137 
1.4 「 � 
1.2 T 
(0 T ^ 
• • • • • • 
0.0 ‘ , W K ^ M 
Control 0.3 AP 0.6 AP 
HMGR | | p i | | i 
p-tubul in • • v H P ' i i i i i i i ^ K ; 
Figure 4. 8. 
Relative abundance of hepatic HMGR immunoreactive mass as determined by 
Western Blot analysis. Data are normalized with (3-tubulin so that value of the 
control group is treated as 1.0. Values are expressed as means 土 S.D. (n=13). 
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Figure 4. 9 
Relative abundance of hepatic CYP7A1 immunoreactive mass as determined 
by Western Blot analysis. Data are normalized with p-tubulin so that value of 
the control group is regarded as 1.0. Values are expressed as means 土 S.D. 
(n=13). 
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4.3.12 Effect of AP on liver cholesterol level 
Hepatic cholesterol concentrations of the animals are shown Figure 4. 10. There 
was no significant difference in cholesterol concentrations in the liver of the control 
group and the AP fed groups. 
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Figure 4.10 
Hepatic cholesterol concentration in the hamsters as determined by GC. 
Values are expressed as means 土 S.D. (n=13). 
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4.4 Discussion 
Consumption of apples had been shown to reduce blood cholesterol in humans 
(Mee & Gee，1997) and rats (Aprikian et al, 2002; Aprikian et al, 2003; Gonzalez et 
al, 1998). However, these studies only investigated the effect of pectin (Aprikian et al, 
2003; Gonzalez et al, 1998), whole lyophilized apple fruit (Aprikian et al, 2002) and 
dietary fiber extract/apple pulp (Mee & Gee, 1997) on blood cholesterol. The present 
study focused on how AP extract affected blood cholesterol. 
To the best of our knowledge, the present study was the first time to demonstrate 
that supplementation of AP did not affect plasma TC, but it increased 
HDL-cholesterol, resulting in a reduced nHDL-C/HDL-C ratio (Table 4.4). This is in 
agreement with a study on Wistar rats by Nakazato (2006) who reported that apple 
polyphenols had no hypocholesterolemic activity, but they did not measure cholesterol 
distribution in different lipoprotein classes. In another study, consumption of apple 
juice was found to have no significant effect on blood TC or HDL-C in children 
(Dennison et al, 1999). The discrepancy from the present finding might be because 
they used human children as subjects and apple juice instead of AP extract was 
studied. 
The present study also demonstrated that AP supplementation reduced CETP 
activity both in vitro and in vivo. As shown in Figure 4.3, at sufficiently high 
concentrations, AP acted as an inhibitor to CETP in vitro and such property was 
confirmed in vivo, finding that AP-fed hamsters had CETP activity lower than the 
control group (Figure 4.4). Western Blotting showed no difference in plasma CETP 
immunoreactive mass between the AP-fed and control hamsters, suggesting that AP 
did not affect expression of CETP protein in hamsters. This clearly showed that AP 
did not regulate translation of CETP gene but it inhibited its enzyme activity in 
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plasma. 
In recent years, inhibiting CETP activity as a strategy of raising blood HDL 
cholesterol has become a popular investigation topic (Barter & Kastelein, 2006; 
Doggrell，2006; Dullaart et al, 2007; Klerkx et al, 2006; Okamoto et al, 2007; Shah, 
2007; Van der Steeg et al, 2005). The present study is in agreement with those of 
Kothari (1997) and Rittershaus (2000) who showed that inhibition of CETP activity 
was associated with an increase in blood HDL-cholesterol level. Elevated 
HDL-cholesterol has been shown to be associated with lower risks of cardiovascular 
diseases and myocardial infarctions (Pischon et al, 2005). Both of the AP-fed groups 
had lower non-HDL-cholesterol to HDL-cholesterol ratio, suggesting that AP 
modified lipoprotein profile favorably against atherosclerosis (Kawamoto et al, 2005). 
Previous studies reported that whole apple fruit, apple fiber and apple pectin 
reduced TC in animals (Gonzalez et al, 1998; Karvinen & Miettinen， 1968; 
Leontowicz et al, 2003) but apple polyphenol extract alone did not affect TC level in 
rats (Nakazato et al, 2006). Together with the present study, the fiber and pectin in 
apple could reduce the total cholesterol while AP could affect the distribution of 
cholesterol among lipoprotein classes. In other words, apples contain at least two 
classes of substances that could improve blood cholesterol independently. 
The present study did not find evidence that AP could affect SREBP-2, LDL-R, 
HMGR and CYP7A1, at both transcriptional and translational levels. It is unknown 
how AP affects plasma CETP activity. It was reported that heavy alcohol consumption 
reduced carbohydrate content in CETP, leading to a defected CETP (Liinamaa et al, 
2006). Whether AP affects plasma CETP activity in the same way is not known. It 
should be noted that polyphenols undergo significant structural modification once 
they are absorbed into enterocytes and in the liver by cytochrome P450 enzymes 
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(Kroon et a!’ 2004). It deems neeessaiy to, investigate the chemical form of apple 
polyphenols and to investigate their effects on CETP glycosylation. 
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Arterial cholesterol deposition due to hypercholesterolemia has been established 
to closely associate with the development of atherosclerosis. Dietary PUFAs and 
phytochemicals have been shown to improve blood lipid profile and slow down 
atherosclerosis progression. 
LA, CLA, LN and CLN are four structurally similar ODA. The present study 
demonstrated that only incorporation of 2% (w/w) LA, CLA and LN but not CLN in 
the diet was hypocholesterolemic in hamsters. Blood TC was decreased by both LA 
and CLA feeding, but non-HDL cholesterol was reduced to a larger extent by CLA 
than LA, resulting in a significantly lower non-HDL cholesterol/ HDL cholesterol 
ratio. In contrast, LN but not CLN reduced blood total cholesterol and non-HDL 
cholesterol. Hepatic cholesterol level was significantly reduced by the four ODA, with 
CLA reduced the most, followed by LN, CLN and LA. It was concluded that double 
bond conjugation on LA enhances its hypocholesterolemic activity but this has an 
opposite effect for LN. 
No significant difference was found in hepatic protein of SREBP-2, HMGR, 
LDLR, LXR and CYP7A1. No significant difference was found in hepatic mRNA of 
CETP, LDLR, LXR and CYP7A1 either. Plasma CETP activity was not significantly 
affected in hamsters fed ODA. However, cholesterol balance study clearly 
demonstrated that cholesterol retention was significantly decreased by LA, CLA and 
LN, but not CLN. Intestinal ACAT activities of CLA and LN, but not LA and 
CLN-fed hamsters, were significantly lower than the control. It was concluded that 
CLA and LN but not CLN lowered blood total and non-HDL cholesterol through 
145 
inhibition on intestinal ACAT, leading to reduced cholesterol absorption, but had no 
effect on hepatic SREBP-2, HMGR, LDLR, LXR and CYP7A1 at both transcriptional 
and translational levels. 
Supplementation of 0.4 mmol/L of CLA in the medium up-regulated gene 
expressions of SREBP-2, HMGR, LDLR, LXR and CYP7A1 in HepG2. However, 
significant increase in protein abundance was only found in LXR but not SREBP-2, 
HMGR, LDLR or CYP7A1 in CLA treated cells. Supplementation of LA and LN did 
not significantly affect the protein abundance of SREBP-2, HMGR, LDLR, LXR and 
CYP7A1. It was concluded that CLA up-regulated gene expression of SREBP-2, 
HMGR, LDLR, LXR and CYP7A1 and protein abundance of LXR distinctively over 
LA and LN in vitro. 
Hypocholesterolmic effect of AP on CETP activity was studied in vitro and in 
vivo. It was demonstrated that AP inhibited CETP activity in a dose dependent manner 
in vitro. AP concentration of 0.02 mg/ mL or above was found to significantly inhibit 
transfer of cholesterol from HDL to LDL. We then investigated the effect of AP on 
blood cholesterol in hamsters, and found that supplementation of 0.3% or 0.6% of AP 
in the diet did not affect blood TC，but it increased HDL-cholesterol and decreased 
LDL-cholesterol, leading to a reduced non-HDL cholesterol/ HDL-cholesterol ratio. 
TG level was also significantly reduced in hamsters fed 0.6% AP. No significant 
difference was found in hepatic cholesterol level in AP fed hamsters. Protein 
abundance of plasma CETP and hepatic SREBP-2, LDLR, HMGR and CYP7A1 was 
not significantly different in the hamsters. However, plasma CETP activity was 
significantly reduced in both 0.3% and 0.6% AP-fed hamsters. Since no difference in 
plasma CETP protein level was detected, and ex vivo inhibition of CETP by AP was 
found, the inhibition was estimated to occur at a post-translational level. It was 
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concluded that AP had no effect on blood TC but favorably improved distribution of 
cholesterol in lipoproteins through direct inhibition on CETP. 
The activity of LA, CLA, LN and AP to favorably change the blood lipid profile 
was confirmed in the present study. However, only hamsters and in vitro models were 
used to test the activity of ODA and AP on blood cholesterol. There is no information 
whether or how our findings apply to humans. Based on the present results, it deems 
necessary to further investigate the effect of ODA and AP on cholesterol metabolism 
in human subjects. 
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